{"Title": ["ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth", "AMAG Pharmaceuticals Inc (AMAG) Q1 2020 Earnings Call Transcript", "BUZZ-U.S. STOCKS ON THE MOVE-Cellect Biotechnology, Under Armour, AMC Entertainment", "Should You Buy This Stock That Makes \"Viagra for Women\"?", "Why AMAG Pharmaceuticals Struggled Again in Q4", "AMAG Pharmaceuticals Inc (AMAG) Q4 2019 Earnings Call Transcript", "Validea's Top Five Healthcare Stocks Based On Joseph Piotroski - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 1/19/2020", "ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth", "Validea's Top Five Healthcare Stocks Based On Joseph Piotroski - 12/15/2019", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 12/15/2019", "AMAG Pharmaceuticals Inc (AMAG) Q3 2019 Earnings Call Transcript", "AMAG Pharmaceuticals' Q3 Results Overshadowed by Ominous FDA Panel Recommendation", "Top 5 Losers In Healthcare Sector (CYCN, AMAG, ELGX\u2026)", "Why AMAG Pharmaceuticals Is Tanking Today", "It's 9-7 For Withdrawal Of Makena, Roche-Spark Deal Delayed Again, MRK On Watch", "Validea's Top Five Healthcare Stocks Based On Joseph Piotroski - 1/19/2020", "Health Care Sector Update for 10/25/2019: CGIX,IDXG,AMAG,RMD,UHS", "Noteworthy Friday Option Activity: TAP, AMAG, RP", "Health Care Sector Update for 10/25/2019: AMAG,RMD,UHS", "Notable Friday Option Activity: ANET, LYFT, AMAG", "Biotech Stocks Facing FDA Decision In October 2019", "Monday 8/12 Insider Buying Report: AMAG, NFLX", "AMAG Pharmaceuticals Inc (AMAG) Q2 2019 Earnings Call Transcript", "FDA Committee Recommends Removing Makena Drug For Preventing Premature Births", "Why Palatin Technologies Stock Dropped as Much as 21.5% Today", "Health Care Sector Update for 06/24/2019: KRYS,PTN,AMAG,MESO,BMY,CELG", "Health Care Sector Update for 06/24/2019: PTN,AMAG,MESO,BMY,CELG", "Health Care Sector Update for 06/24/2019: PTN, AMAG, MESO, BMY, CELG, JNJ, PFE, ABT, MRK, AMGN", "3 Drug Stocks That Could Win From Key FDA Approvals in June", "Biotech Stocks Facing FDA Decision In June 2019", "Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News", "What's Behind AMAG Pharmaceuticals' Horrible Q2 Results", "Why Is AMAG Pharmaceuticals (AMAG) Down 24.5% Since Last Earnings Report?", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2/17/2019", "AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates", "AMAG Pharmaceuticals (AMAG) Q4 2018 Earnings Conference Call Transcript", "AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Misses Revenue Estimates", "AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 12/16/2018", "AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study", "AMAG's Label Expansion of Lead Products Raises Share Price", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 11/18/2018", "Validea Kenneth Fisher Strategy Daily Upgrade Report - 11/3/2018", "AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues", "AMAG Pharmaceuticals Inc (AMAG) Q3 2018 Earnings Conference Call Transcript", "AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Tops Revenue Estimates", "Here's Why AMAG Pharmaceuticals Tumbled 12.7% Today", "AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals", "Will Cigna (CI) Q3 Earnings Gain on Revenue Growth?", "The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals", "5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings", "AMAG Pharmaceuticals (AMAG) Q3 Earnings Preview: What to Watch Ahead of the Release", "Is a Beat in Store for Zoetis (ZTS) This Earnings Season?", "Commit To Buy AMAG Pharmaceuticals At $17, Earn 10.5% Annualized Using Options", "Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?", "What's in the Cards for Novavax (NVAX) This Earnings Season?", "AMAG In-Licenses Global Rights to Orphan Drug Candidate", "AMAG Pharmaceuticals Becomes Oversold", "Options Traders Expect Huge Moves in AMAG Pharmaceuticals (AMAG) Stock", "Validea's Top Five Healthcare Stocks Based On Joseph Piotroski - 8/19/2018", "Health Care Sector Update for 06/15/2018: RDY,TEVA,AMAG,BGNE", "Health Care Sector Update for 06/15/2018: TEVA,AMAG,BGNE", "Health Care Sector Update for 06/04/2018: DCPH,LOXO,PTN,AMAG,VXRT", "New Strong Sell Stocks for October 5th", "AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View", "Teva (TEVA) to Report Q1 Earnings: What's in the Cards?", "AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?", "AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues", "These 2 Biotech Stocks Are Soaring. Can They Keep It Up?", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2/18/2018", "Mid-Day Market Update: SolarEdge Technologies Gains Following Q4 Earnings Beat; Avid Bioservices Shares Slide", "Health Care Sector Update for 06/04/2018: LOXO,PTN,AMAG,VXRT", "AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View", "Teva (TEVA) to Report Q1 Earnings: What's in the Cards?", "AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?", "Health Care Sector Update for 02/15/2018: AMAG,ATRS,CDMO,ZTS,ARWR", "Mid-Afternoon Market Update: Build-A-Bear Surges On Upbeat Earnings; Inpixon Shares Drop", "Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today", "Health Care Sector Update for 02/05/2018: JNJ, PFE, ABT, MRK, AMGN, SPPI, CAPR, AMAG, CRIC, BMY, MGEN", "Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today", "Health Care Sector Update for 02/05/2018: SPPI,AMAG,CTIC", "Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February", "Commit To Purchase AMAG Pharmaceuticals At $12, Earn 43.9% Annualized Using Options", "Surprising Analyst 12-Month Target For FTXH", "TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why", "Health Care Sector Update for 12/20/2017: ATOS,AMAG,APDN,EGLT", "AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook", "Health Care Sector Update for 02/05/2018: MGEN,SPPI,AMAG,CTIC", "Mid-Day Market Update: Dow Surges Over 100 Points; DURECT Shares Plummet", "AMAG Pharmaceuticals (AMAG) Down 6.6% Since Earnings Report: Can It Rebound?", "AMAG's Filing for Feraheme's Label Expansion Accepted by FDA", "AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2", "Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%", "AMAG Pharmaceuticals Focuses on Product Development & Buyouts", "Why Is AMAG Pharmaceuticals (AMAG) Down 15.6% Since the Last Earnings Report?", "Adamas Pharmaceuticals, Inc.: Substantial Upside For A Misunderstood Drug Maker", "Bear of the Day: AMAG Pharmaceuticals (AMAG)", "What Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?", "After Hours Most Active for May 4, 2017 : BAC, JNPR, PFE, GM, FCX, CF, SBUX, CMCSA, YHOO, QCOM, STX, AMAG", "AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y", "AMAG Files for FDA Approval of Subcutaneous Form of Makena", "TherapeuticsMD Falls on Likely Delay in TX-004HR Approval", "Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals", "Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day", "Billionaires' Worst Healthcare Stock Picks for 2017 (So Far)", "Here's Why Natera, Inc. Is Tumbling Today", "AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates", "Earnings Reaction History: AMAG Pharmaceuticals, Inc, 20.0% Follow-Through Indicator, 5.1% Sensitive", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?", "Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?", "5 Toxic Stocks to Get Rid Of or Play Short to Make Gains", "Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?", "Wall Street Poised for Rally After Upbeat Jobs Data", "US Futures Modestly Higher Ahead of Jobs Data", "AMAG Down Despite Positive Data on Makena Auto-Injector", "GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?", "Mid-Morning Market Update: Markets Open Lower; Facebook Beats Q4 Estimates", "Here's Why AMAG Pharmaceuticals Is Falling Today", "Teva (TEVA) Q4 Earnings: What's in Store for the Stock?", "AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder", "Why AMAG Pharmaceuticals, Inc. Is Falling Today", "New Strong Sell Stocks for January 9th", "Health Care Sector Update for 01/09/2017: ARIA,ETRM,AMAG", "Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide", "Health Care Sector Update for 01/09/2017: PTX, ETRM, AMAG, SNY, PTN", "Commit To Purchase AMAG Pharmaceuticals At $26, Earn 12.1% Annualized Using Options", "Is AMAG Pharmaceuticals (AMAG) A Good Value Pick?", "AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder", "AMAG Issues Encouraging Updates on Makena & Feraheme", "Steven Cohen Increases Position in Dynavax", "Why AMAG Pharmaceuticals, Inc. Is Tanking Today", "10 Biotech And Specialty Pharma Bargains - Do You Have The Guts To Speculate?", "Why AMAG Pharmaceuticals, Inc. Plunged 19.2% in May", "Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?", "Where Will AMAG Pharmaceuticals Be 1 Year From Now?", "New Strong Sell Stocks for May 18th", "AMAG (AMAG) Q1 Earnings Beat Estimates, Keeps 2016 View", "Gilead Presents Multiple HCV and HBV Data at Liver Congress", "Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals", "Merck Offers Positive Data from Comparative Trial on Zepatier", "Intrexon (XON) Gains Following Deals with Two Startups", "Repros Reveals Positive Data on Proellex for Uterine Fibroids", "New Strong Sell Stocks for May 19th", "Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance", "Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study", "GW Pharmaceuticals Begins Another Phase III Epidiolex Trial", "Regeneron, Intellia Strike Deal for CRISPR/Cas Platform", "TrovaGene Inks Strategic Partnership with Stratose, Stock Up", "VIVUS (VVUS) Upgraded to Hold on Strong Fundamentals", "Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data", "Valeant (VRX) Receives Notice of Default: Stock in Trouble?", "Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance", "Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study", "Incyte Buys Rights to Jakafi for Graft-Versus-Host Disease", "4 Top Ranked Healthcare Stocks that Surged Last Session", "4 Value Stocks that Suggest Earnings Growth of 50% or More", "Pfizer/Merck KGaA Initiate Avelumab-Inlyta Combo Study", "Ironwood Slumps, Halts Development of Gastroparesis Drug", "AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned", "AbbVie Up, Wins CHMP Backing for Humira's Expanded Use", "Intrexon Ties up with External Investors for Type I Diabetes", "4 Great Stocks to Ride the IBB Rebound", "Baxalta Adynovate Gets Japanese Approval for Hemophilia A", "Gilead Descovy Wins FDA Nod, To Buy Nimbus Liver Program", "Glaxo's (GSK) Strimvelis Gets CHMP Nod for Rare Disorder", "Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use", "The Zacks Analyst Blog Highlights: Edwards Lifesciences, PRA Health Sciences, Gilead Sciences, AMAG Pharmaceuticals and Horizon Pharma", "Dr. Reddy's Acquires Anticancer Drug Rights from Eisai", "Gilead Seeks Approval for Tenofovir Alafenamide in Japan", "Valeant Pharmaceuticals (VRX) Still a Strong Sell Stock", "Inovio (INO) Offers Update on Development Plan for INO-3112", "3 Biotech Stocks That Make the Grade for Investors", "Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 5%", "Puma's (PBYI) Filing for Breast Cancer Drug Neratinib Delayed", "Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies", "Apricus Hits 52-Week Low on Unfavorable Fispemifene Data", "Alder (ALDR) Surges on Positive Data on Migraine Candidate", "BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU", "Portola Hits 52-Week Low on Unfavorable Betrixaban Data", "Dr Reddy's Collaborates with XenoPort for Psoriasis Drug", "Pfizer's Revised Filing for Xeljanz Accepted for Review in EU", "Regeneron/Sanofi Report Positive Phase III Data on Praluent", "Alexion Pharmaceuticals' Kanuma Gains Approval in Japan", "Bristol-Myers to Buy Padlock, Focus on Autoimmune Diseases", "BioMarin (BMRN) Down on Phase III Data on Pegvaliase", "Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division", "Acorda Gets Favorable Court Ruling in Ampyra Patent Lawsuit", "Bayer's Kovaltry Gets Approval in the U.S. for Hemophilia A", "AMAG Initiates Enrolment in Phase III Study on Feraheme", "Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU", "AstraZeneca's Heart Drug Brilinta Disappoints in Stroke Study", "5 Unbeatable Stocks to Brave the Market Mayhem", "Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up", "Inovio (INO) 4Q Loss Wider than Expected, Pipeline in Focus", "GW Pharmaceuticals Skyrockets on Favorable Epilepsy Data", "MannKind Posts Wider-than-Expected Loss, Afrezza in Focus", "Regeneron/Sanofi Report Positive Sarilumab Phase III Data", "Gilead's Zydelig under EU Review amid Safety Concerns", "Eli Lilly Down, Alters Primary Endpoint of Solanezumab", "Spectrum (SPPI) Incurs Narrower-than-Expected Loss in Q4", "Celldex Advised to Discontinue Phase III Study on Rintega", "Eli Lilly's Ixekizumab Positive in Plaque Psoriasis Studies", "Novo Nordisk Victoza Lowers Cardiovascular Risk Per Study", "Qiagen: Molecular Diagnostics a Drag, Currency Woes Persist", "Avalanche (AAVL) Reports Wider-than-Expected Loss in Q4", "Earnings Estimates Moving Higher for AMAG Pharmaceuticals (AMAG): Time to Buy?", "Pfizer's Lung Cancer Drug Xalkori Label Expanded in U.S.", "Horizon (HZNP) Misses on Q4 Earnings, Beats on Revenues", "Emergent (EBS) Beats on Q4 Earnings, Revenues Up Y/Y", "QLT (QLTI) Reports Narrower-than-Expected Loss in Q4", "Bayer (BAYRY) Q4 Earnings Lag Estimates, Gives 2016 View", "Can the Uptrend Continue for AMAG Pharmaceuticals (AMAG)?", "BioMarin Incurs Loss in Q4, Misses Estimates, Gives '16 View", "Alkermes Q4 Loss Narrower than Expected, Updates Pipeline", "BioMarin (BMRN) Presents Positive Data on Cerliponase Alfa", "Bull of the Day: AMAG Pharma (AMAG)", "Why You Shouldn't Bet Against AMAG Pharmaceuticals (AMAG) Stock", "New Strong Buy Stocks for February 23rd", "Last Week's Best Healthcare ETF", "AMAG Q4 Earnings & Revenues Up Y/Y, Gives 2016 Outlook", "3 Value Stocks Near 52-Week Lows Worth Buying", "Health Care Sector Update for 01/04/2016: AMAG,UNIS,MYMX", "AMAG Pharmaceuticals, Oil States International, USA Compression, McDermott International, Powersecure International and Facebook highlighted as Zacks Bull and Bear of the Day", "Bull of the Day: AMAG Pharma (AMAG)", "AMAG Responds to FDA's CRL for Single-Dose Vial of Makena", "Health Care Sector Update for 11/19/2015: LLY, MRK, ATHX, AMAG", "AMAG Receives Another CRL for Single-Dose Vial of Makena", "Mid-Afternoon Market Update: Kirkland's Drops On Downbeat Earnings; Perry Ellis Shares Spike Higher", "Weakness Seen in AMAG Pharmaceuticals (AMAG) Estimates: Should You Stay Away?", "New Strong Sell Stocks for November 9th", "7 Best Cheap Stocks to Buy for 2016", "Health Care Sector Update for 11/03/2015: AMAG, MDCO, ISIS", "Mid-Afternoon Market Update: Dow Rises 125 Points; RetailMeNot Shares Climb On Earnings Beat", "Why AMAG Phamaceuticals Shares Are Crashing Today", "QLT (QLTI) Reports Narrower-than-Expected Loss in Q3", "Bayer (BAYRY) Q3 Revenues Up Y/Y, 2015 View Adjusted", "GNC Holdings Earnings, Revenues Lag; Franchise Unit Strong", "Keryx Q3 Loss Wider-than-Expected, Auryxia in Focus", "Mid-Day Market Update: US Stocks Rise; TASER Shares Drop On Downbeat Earnings", "Qiagen Misses on Q3 Earnings and Revenues, Liquidity Strong", "Affymetrix Beats Q3 Earnings, Lags Sales, Margins View Up", "Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View", "AMAG to Initiate Head-to-Head Phase III Study on Feraheme", "Theravance's Q3 Loss Wider than Expected, Revenues Miss", "ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q1", "BioMarin's Q3 Loss Narrower than Expected, Outlook Revised", "Alexion (ALXN) to Report Q3 Earnings: What to Expect?", "Spectrum (SPPI) Initiates Phase III on Apaziquone Under SPA", "Can Bristol-Myers (BMY) Sustain Earnings Momentum in Q3?", "What's in Store for Gilead (GILD) this Earnings Season?", "Baxter International (BAX) Q3 Earnings: Surprise in Store?", "Keryx to Raise $125M Through Private Placement of Notes", "3 Biotech Stocks With Astonishingly Low P/E Ratios", "New Strong Buy Stocks for October 27th", "J&J to Sell Sugar Substitute Splenda to Heartland Food", "Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio", "Vical's Antifungal Candidate VL-2397 Receives QIDP Status", "Merck's Keytruda under FDA Review for First-Line Melanoma", "AVEO Pharmaceuticals (AVEO) in Focus: Stock Soars 45.3%", "Should AMAG Pharmaceuticals (AMAG) Be On Your Radar Now?", "BioLineRx Up on Phase IIb Study Initiation on Leukemia Drug", "Akebia (AKBA) Skyrockets on Encouraging Phase II Data", "J&J to Sell Sugar Substitute Splenda to Heartland Food", "Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio", "Acceleron Pharma (XLRN) Moves 13.3% Higher in Session", "Emergent BioSolutions Gets $44M CDC Contract for VIGIV", "Myriad: Medicare Coverage for Prolaris Prostrate Cancer Test", "Integra's Acquisitions to Buoy Growth in '15, Currency Woes Stay", "BioDelivery's New Onsolis Formulation Gains FDA Approval", "Seattle Genetics' Adcetris Label Expanded in the U.S.", "AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint", "Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer", "Novavax (NVAX) Shows Strength: Stock Moves Up 24.1%", "Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8%", "Pluristem (PSTI) Provides Update on PLX-PAD Cells in Japan", "BioScrip's Strategic Plans Offer Hope, Margin Concerns Stay", "MannKind (MNKD) Reports Narrower-than-Expected Q2 Loss", "VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%", "BioDelivery Incurs Wider Loss in Q2, Revenues Fall Y/Y - Analyst Blog", "Collegium's Xtampza to be Reviewed by FDA Advisory Panels - Analyst Blog", "Emergent BioSolutions Tops on Q2 Earnings, Plans Spin-Off - Analyst Blog", "Alnylam's Q2 Loss Wider than Expected, Revenues Fall Short - Analyst Blog", "Use Options For a Chance To Buy AMAG at a 18% Discount", "Genomic Health Q2 Loss Wider than Expected; Tests Ramp Up - Analyst Blog", "Nektar Q2 Loss Wider-than-Expected, Outlook Maintained - Analyst Blog", "Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog", "Osiris Therapeutics' Q2 Earnings & Revenues Grow Y/Y - Analyst Blog", "Incyte Q2 Loss Narrower-than-Expected, Ups Jakafi Outlook - Analyst Blog", "BioMarin Q2 Loss Narrower than Expected, Maintains Outlook - Analyst Blog", "VIVUS (VVUS) Q2 Loss Narrower, Restructuring Announced - Analyst Blog", "Qiagen (QGEN) Beats Q2 Earnings, Revenues; Keeps '15 View - Analyst Blog", "Amgen Beats on Q2 Earnings & Revenues, Raises Outlook - Analyst Blog", "Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog", "SurModics (SRDX) Beats on Q3 Earnings, Improves Outlook - Analyst Blog", "Osiris Therapeutics' Q2 Earnings & Revenues Grow Y/Y - Analyst Blog", "Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - Analyst Blog", "Why AMAG Pharmaceuticals (AMAG) Might Be a Diamond in the Rough - Tale of the Tape", "Theravance's Q2 Loss Wider-than-Expected, Revenues Miss - Analyst Blog", "Cytori Therapeutics (CYTX) Jumps: Stock Moves Up 10% - Tale of the Tape", "Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog", "Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5% - Tale of the Tape", "Alkermes' Reports Wider Q2 Loss, Increases Guidance - Analyst Blog", "Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog", "Will Varian Medical's (VAR) Q3 Earnings Impress Investors? - Analyst Blog", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.6% - Tale of the Tape", "Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog", "AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog", "XOMA Crashes after Gevokizumab Misses Primary Endpoint - Analyst Blog", "Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog", "Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog", "Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog", "Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog", "Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog", "Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog", "Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog", "Should You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? - Tale of the Tape", "Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog", "Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog", "Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog", "Gilead (GILD) Presents Encouraging Data on HIV Candidate - Analyst Blog", "Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13% - Tale of the Tape", "Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog", "Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog", "Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog", "BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog", "Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog", "AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog", "Can C.R. Bard (BCR) Surprise Earnings Estimates in Q2? - Analyst Blog", "Asterias Biotherapeutics (AST) Looks Good: Stock Up 13.4% - Tale of the Tape", "Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog", "Hospira (HSP) Launches Generic Angiomax in the U.S. - Analyst Blog", "AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog", "Amgen Reports Positive Data on Leukemia Drug Blincyto - Analyst Blog", "Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog", "AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog", "Ohr Pharmaceutical Jumps on Positive Eye Drug Study Data - Analyst Blog", "Sanofi Unveils Restructuring Plans, Prunes Business Units - Analyst Blog", "MiMedx (MDXG) Worth a Look: Stock Adds 5.3% in Session - Tale of the Tape", "Synthetic Biologics (SYN) in Focus: Stock Rises 14.6% - Tale of the Tape", "Cytokinetics (CYTK) Jumps: Stock Adds 6.8% in Session - Tale of the Tape", "Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog", "Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.3% - Tale of the Tape", "Exelixis' Cabozantinib in Phase I for Genitourinary Cancers - Analyst Blog", "AstraZeneca's (AZN) Oncology Drug Iressa Label Expanded - Analyst Blog", "Qiagen's EGFR Test Gets PMA Nod to Treat Lung Cancer - Analyst Blog", "Vital Therapies (VTL) Looks Good: Stock Up 5.5% in Session - Tale of the Tape", "Biogen (BIIB) Slips 2.8%, Lead R&D Executive Set to Leave - Analyst Blog", "Eyegate-Valeant Team Up for EGP-437; Share Gains for Both - Analyst Blog", "Celgene to Buy Receptos; Reports Q2 Preliminary Results - Analyst Blog", "Lilly Provides Update on Necitumumab FDA Advisory Panel - Analyst Blog", "Novavax (NVAX) Looks Good: Stock Moves 11% Higher - Tale of the Tape", "XOMA Corporation in Focus: Stock Adds 20.7% in Session - Tale of the Tape", "Neogenomics (NEO) in Focus: Stock Surges 25.2% - Tale of the Tape", "China Biologic Products (CBPO) in Focus: Stock Up 5.7% - Tale of the Tape", "AstraZeneca Divests Ex-U.S. Rights to Entocort for $215M - Analyst Blog", "Aquinox Shares Nosedive after Lead Candidate Disappoints - Analyst Blog", "AbbVie (ABBV) Gains on Label Expansion of Imbruvica in EU - Analyst Blog", "3 Top Ranked Health Care Stocks to Buy this Earnings Season - Stocks in the News", "A Pair of T. Rowe Price Small-Cap Funds Go Their Own Way", "Dyax Hereditary Angioedema Drug Gets Breakthrough Status - Analyst Blog", "Vanda's Sleep Disorder Drug Hetlioz Gains Approval in EU - Analyst Blog", "Dynavax Technologies (DVAX) in Focus: Stock Up 8.2% - Tale of the Tape", "Catabasis Up on Fast Track Status for DMD Drug CAT-1004 - Analyst Blog", "Isis Pharmaceuticals' Lipid Disorder Drug Gets Orphan Status - Analyst Blog", "Forget Baxter, Grab These 3 Medical Stocks Instead - Analyst Blog", "3 Top Ranked Health Care Stocks to Buy this Earnings Season - Stocks in the News", "AMAG Pharmaceuticals (AMAG) is in Overbought Territory: What's Next? - Tale of the Tape", "Zacks Rank #5 Additions for Friday - Tale of the Tape", "10 Most Profitable Companies in Healthcare", "AMAG Beats on Q1 Earnings & Revenues, Ups View - Analyst Blog", "Use Options For a Chance To Buy AMAG at a 27% Discount", "Zacks Rank #5 Additions for Tuesday - Tale of the Tape", "AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog", "Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog", "Use Options For a Chance To Buy AMAG at a 20% Discount", "First Week of April 17th Options Trading For AMAG Pharmaceuticals", "AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog", "Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog", "Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog", "Allergan Beats Earnings Yet Again on Strong Revenues - Analyst Blog", "Use Options For a Chance To Buy AMAG at a 28% Discount", "bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog", "Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog", "Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog", "Biogen Idec (BIIB) Shows Strength: Stock Moves Up 10.2% - Tale of the Tape", "SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog", "Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 5.8% - Tale of the Tape", "Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog", "Glaxo Posts In Line Q4 Earnings, HIV Segment Sales Grow - Analyst Blog", "CEL-SCI Corp. (CVM) in Focus: Stock Adds 7.5% in Session - Tale of the Tape", "Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog", "Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog", "AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8% - Tale of the Tape", "Bayer Announces Updates to European Label of Xarelto - Analyst Blog", "Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog", "Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog", "Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog", "Coronado Biosciences (CNDO) Looks Good: Stock Up 7.4% - Tale of the Tape", "Celldex Therapeutics (CLDX) Jumps: Stock Moves Up 8.9% - Tale of the Tape", "Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog", "Novavax (NVAX) Jumps: Stock Adds 6.4% in Session - Tale of the Tape", "Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst Blog", "Illumina Unveils 3 NGS Systems, Modifies Business Strategy - Analyst Blog", "Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog", "Actavis/Gedeon Richter Present Schizophrenia Drug Data - Analyst Blog", "CorMedix (CRMD) Shows Strength: Stock Moves Up 14.6% - Tale of the Tape", "Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog", "Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst Blog", "Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog", "BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog", "Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst Blog", "Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal - Analyst Blog", "AstraZeneca Announces Encouraging Data from Brilinta Study - Analyst Blog", "Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst Blog", "Pharmacyclics Reports Preliminary Results and 2015 Outlook - Analyst Blog", "Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst Blog", "Bristol-Myers Opdivo Study Stopped on Favorable Data - Analyst Blog", "Vical Incorporated (VICL) Jumps: Stock Adds 9.5% in Session - Tale of the Tape", "Agenus Soars on Immuno-Oncology Agreement with Incyte - Analyst Blog", "Conatus Announced Results from Emricasan Studies - Analyst Blog", "Discovery Laboratories (DSCO) Jumps: Stock Rises 6.7% - Tale of the Tape", "Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog", "Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog", "Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst Blog", "Coherus Biosciences (CHRS) Jumps: Stock Adds 7.7% in Session - Tale of the Tape", "Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog", "AbbVie 2015 Earnings Guidance Projects Strong Y/Y Growth - Analyst Blog", "Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog", "AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog", "Alkermes Soars on Positive Schizophrenia Drug Results - Analyst Blog", "Intercept Pharmaceuticals (ICPT) Crumbles: ICPT Falls 9.6% in Session - Tale of the Tape", "Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog", "CytRx Jumps on Positive Results from Brain Cancer Study - Analyst Blog", "Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst Blog", "Macrocure (MCUR) Shows Strength: Stock Moves 5.4% Up - Tale of the Tape", "Kite Pharma (KITE) Looks Good: Stock Adds 15.1% in Session - Tale of the Tape", "Arena Pharmaceuticals Soars on Positive Study Results - Analyst Blog", "Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog", "Bristol-Myers Inks Deal for Fibrotic Disease Treatments - Analyst Blog", "Aquinox Starts Dosing for an Atopic Dermatitis Study - Analyst Blog", "Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog", "ProQR Therapeutics (PRQR) Jumps: Stock Adds 6% in Session - Tale of the Tape", "Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog", "Hospira's Dyloject Cleared in the U.S. for Pain Management - Analyst Blog", "Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst Blog", "Why You Shouldn't Bet Against AMAG Pharmaceuticals (AMAG) Stock - Tale of the Tape", "AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog", "Athersys Finishes Enrollment for MultiStem Cell Therapy Trial - Analyst Blog", "Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog", "bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog", "Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog", "Celldex's Glembatumumab Vedotin in Phase II for Melanoma - Analyst Blog", "Zacks Rank #1 Additions for Tuesday - Tale of the Tape", "CytRx Falls on Written FDA Notice for Aldoxorubicin Study - Analyst Blog", "AMAG Pharma (AMAG) Shares March Higher, Can It Continue? - Tale of the Tape", "Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog", "Mylan, Gilead Ink Deal for TAF-based HIV Drugs - Analyst Blog", "Celgene Hits 52-Week High on Positive CHMP Opinion - Analyst Blog", "Glaxo's Ebola Candidate Well-Tolerated in Early U.S. Study - Analyst Blog", "uniQure N.V. (QURE) in Focus: Stock Soars 17.6% - Tale of the Tape", "Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog", "Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape", "AMAG Pharmaceuticals (AMAG): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape", "Alexion's Soliris Gets Final Positive NICE Recommendation - Analyst Blog", "Mylan (MYL) Sued By Baxter for Generic Filing of Brevibloc - Analyst Blog", "Merge Healthcare, Primordial to Improve Radiology Solutions - Analyst Blog", "Strength Seen in Kythera (KYTH): Stock Moves 5.5% Higher - Tale of the Tape", "What Makes BioDelivery Sciences (BDSI) a Strong Sell? - Tale of the Tape", "Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape", "Isis Pharmaceuticals Earns Milestone on Study Initiation - Analyst Blog", "Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog", "Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape", "Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape", "Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog", "Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape", "Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape", "Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan - Analyst Blog", "XOMA Corp Worth Watching: Stock Moves 10.3% Higher - Tale of the Tape", "EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 15.9% - Tale of the Tape", "Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape", "Novavax Gains on Fast Track Designation for RSV F Vaccine - Analyst Blog", "TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog", "Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status - Analyst Blog", "Myriad's Vectra DA: A Better Indicator for Rheumatoid Arthritis - Analyst Blog", "Celgene's PDE4 Inhibitor Otezla Gets Positive CHMP Opinion - Analyst Blog", "Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape", "Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape", "Omnicell Offers Advanced OT Automation at Hospital in Riyadh - Analyst Blog", "Illumina, bioMerieux to Co-develop NGS Epidemiology Solution - Analyst Blog", "Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape", "Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape", "Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape", "Argos Therapeutics (ARGS) Jumps: Stock Gains 7.4% - Tale of the Tape", "Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog", "Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape", "Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog", "Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog", "Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog", "Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog", "Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape", "Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog", "AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog", "Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog", "Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog", "Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape", "PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog", "Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog", "Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog", "AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog", "Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog", "Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape", "Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog", "VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog", "Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog", "Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog", "Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog", "Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog", "Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog", "Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog", "MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog", "Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog", "Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog", "Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog", "Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog", "Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog", "AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape", "Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog", "Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? - Analyst Blog", "Will Expedia Inc.'s (EXPE) Earnings Surprise this Season? - Analyst Blog", "Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog", "Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog", "Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog", "Allergan Beats on Earnings, Revenues; Valeant Raises Offer - Analyst Blog", "Zacks Rank #1 Additions for Monday - Tale of the Tape", "Can Corning (GLW) Surprise Earnings Estimates This Season? - Analyst Blog", "Will Baidu (BIDU) Disappoint Q3 Earnings Estimates? - Analyst Blog", "Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog", "Can the Rally in AMAG Pharmaceuticals (AMAG) Shares Continue? - Tale of the Tape", "AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog", "Sector Update: Health Care Stocks Slightly Lower; AMAG Pharma Springs Higher on $675 Mln Deal for Lumara Health", "Sector Update: Health Care", "AMAG Pharmaceuticals (AMAG) is Overbought: Is A Drop Coming? - Tale of the Tape", "AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog", "Sector Update: Health Care Stocks Hang On for Small Gains; AMAG Pharma Climbs After Topping Analyst Expectations", "Thursday's ETF Movers: XBI, GDXJ", "Why AMAG Pharmaceuticals (AMAG) Could Be Positioned for a Slump - Tale of the Tape", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "AMAG Pharma (AMAG) is in Overbought Territory: What's Next? - Tale of the Tape", "Zacks Rank #5 Additions for Tuesday - Tale of the Tape", "Wider-than-Expected Q1 Loss at AMAG - Analyst Blog", "Wider-than-Expected Q4 Loss at AMAG - Analyst Blog", "AMAG Slides on Regulatory Setback - Analyst Blog", "Sector Update: Health Care", "Update on AMAG's Feraheme - Analyst Blog", "BioMarin Seeks Canadian Approval - Analyst Blog", "Positive Data on ChemoCentryx Candidate - Analyst Blog", "AMBI Plunges on Disappointing FDA News - Analyst Blog", "Cytokinetics Progresses with Tirasemtiv - Analyst Blog", "MYGN Unveils Prolaris Study Results - Analyst Blog", "Oculus Gains on Scar Product Approval - Analyst Blog", "AMAG's Feraheme Revs Look Good - Analyst Blog", "Affymetrix Remains Outperform - Analyst Blog", "MYGN Battles Odds, Shares Fall - Analyst Blog", "FDA Agrees to BDSI's Phase III Program - Analyst Blog", "Orphan Drug Status for CNAT's Emricasan - Analyst Blog", "Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 6.6% - Tale of the Tape", "XOMA Corporation (XOMA) Worth Watching: Stock Surges 22.2% - Tale of the Tape", "MiMedx Group (MDXG) in Focus: Stock Moves Up 5.9% - Tale of the Tape", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "Aeterna Zentaris Closes Public Offering - Analyst Blog", "Bayer Hits 52-Week High - Analyst Blog", "AMAG Raised to Strong Buy - Analyst Blog", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "MDCO Progresses with Fibrocaps - Analyst Blog", "Dynavax Technologies (DVAX) Catches Eye: Stock Rises 5.2% - Tale of the Tape", "Athersys (ATHX) Jumps: Stock Rises by 9.2% - Tale of the Tape", "Oncothyreon Inc. (ONTY) in Focus: Stock Up 5.2% - Tale of the Tape", "Vertex Monetizes Incivo Royalty - Analyst Blog", "AMAG Upgraded to Strong Buy - Analyst Blog", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "FDA Go-Ahead for Illumina's Offerings - Analyst Blog", "Synta Pharmaceuticals (SNTA) Catches Eye: Stock Surges 15.2% - Tale of the Tape", "BioMarin Pharmaceutical (BMRN) in Focus: Stock Jumps 7.7% - Tale of the Tape", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Aegerion Pharmaceuticals (AEGR) Catches Eye: Stock Up 5.5% - Tale of the Tape", "Dendreon Narrows Loss, Provenge Disappoints Again - Analyst Blog", "Zacks #1 Rank Additions for Thursday - Tale of the Tape", "FDA Accepts NPS Pharma's sNDA - Analyst Blog", "Medicines Co. Gains on QIDP Status - Analyst Blog", "Vanda Pharmaceuticals, Inc. (VNDA) Grabs Attention: Stock Shoots 95.9% - Tale of the Tape", "AstraZeneca to Invest in New Zoladex Facility - Analyst Blog", "AVEO Q3 Loss Wider than Expected, Shares Down - Analyst Blog", "Vanda Pharmaceuticals (VNDA) Worth Watching: Stock Up 11.9% - Tale of the Tape", "Arena Pharmaceuticals (ARNA) Worth a Look: Stock Surges 10.6% - Tale of the Tape", "Rigel Narrows Loss, Shares Continue to Fall - Analyst Blog", "Loss Narrows at Repros, Shares Down - Analyst Blog", "Geron Q3 Loss in Line; Shares Up on ASH Abstract - Analyst Blog", "PCYC Beats on Earnings and Revs in Q3 - Analyst Blog", "Sequenom Inc. (SQNM) Worth a Look: Stock Surges 24.12% - Analyst Blog", "Jazz Pharma Upgraded to Strong Buy - Analyst Blog", "Chelsea Therapeutics (CHTP) Worth Watching: Stock Surges 11% - Tale of the Tape", "Genomic Health Tops Q3 Earnings Ests - Analyst Blog", "Earnings Beat at SurModics in Q4 - Analyst Blog", "NPSP's Loss Narrows, Shares Down on Weak Forecast - Analyst Blog", "ARIAD Shares Tumble on Iclusig Woes - Analyst Blog", "Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog", "Q1 Earnings Beat at MYGN, Revs Outperform - Analyst Blog", "Narrower-than-Expected Loss at Endocyte - Analyst Blog", "Narrower-than-Expected Q3 Loss at Nektar - Analyst Blog", "Genomic Health Tops Q3 Earnings Ests - Analyst Blog", "Impax Earnings Fall on Lower Revenues - Analyst Blog", "Wider-than-Expected Loss at MannKind - Analyst Blog", "Osiris Up on Q3 Earnings - Analyst Blog", "Wider-than-Expected Loss at Pacira - Analyst Blog", "VRTX Shares Down on Q3 Results - Analyst Blog", "Dr. Reddy's Beats on Earnings - Analyst Blog", "Update on Repros' Pipeline - Analyst Blog", "Q3 Loss at Aegerion Narrower than Expected - Analyst Blog", "Affymetrix Beats on Q3 Earnings - Analyst Blog", "Antiviral Franchise Powers Earnings Beat at Gilead - Analyst Blog", "Avanir Gives Preliminary Update on Fiscal Year 2013 - Analyst Blog", "QIAGEN Beats Both Earnings and Revs - Analyst Blog", "Anacor, Valeant Settle Disputes - Analyst Blog", "Actavis Q3 Earnings Grow, Guides Up - Analyst Blog", "Novo Nordisk Beats on Earnings, Lags Sales - Analyst Blog", "Illumina Tops Earnings, Ups Guidance - Analyst Blog", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Alimera Down on 3rd Iluvien CRL - Analyst Blog", "Anacor Shares Rise on Favorable Arbitration - Analyst Blog", "Strength Seen in Alkermes (ALKS): Stock Up 8.5% - Analyst Blog", "Positive Data on Omeros' OMS824 - Analyst Blog", "FDA Approves Novo Nordisk's NovoEight - Analyst Blog", "Narrower Q3 Loss at AMAG - Analyst Blog", "Another Milestone for Isis Pharma - Analyst Blog", "FDA Delays Verdict for AMAG's Feraheme - Analyst Blog", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "AMAG Pharmaceuticals, Inc. Enters Oversold Territory - Tale of the Tape", "Good News for Catalyst Pharma's Pipeline - Analyst Blog", "Insmed's Arikace Makes Progress - Analyst Blog", "Encouraging Data on Protalix Candidate - Analyst Blog", "Actelion Beats on Earnings and Revenues in Q3 - Analyst Blog", "New Patent Issued for AMAG's Feraheme - Analyst Blog", "Astellas, FibroGen Start Phase II Study - Analyst Blog", "Narrower-Than-Expected Loss at AMAG - Analyst Blog", "Label Expansion Sought for AMAG/TKPYY's Rienso - Analyst Blog", "Swiss Issue for AMAG/Takeda's Rienso - Analyst Blog", "Market Wrap for Wednesday, May 22: Stocks Pullback As Bernanke Says Bond Buying Could Slow", "AMAG Narrows Loss; Maintains View - Analyst Blog", "AMAG Shares Skid on FDA Notification - Analyst Blog", "FDA Action Date for AMAG Drug - Analyst Blog", "AMAG Narrows Loss, Maintains View - Analyst Blog", "AMAG Gives 4Q12 Snapshot - Analyst Blog", "AMAG Seeks Feraheme Label Expansion - Analyst Blog", "AMAG Presents Feraheme Data - Analyst Blog", "AMAG's Rienso Launched in the EU - Analyst Blog", "AMAG Cuts Loss, Guides Favorably - Analyst Blog", "Positive Results on AMAG's Feraheme - Analyst Blog", "AMAG Beats Expectations - Analyst Blog", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "Pre-Market Earnings Report for July 26, 2012 : MMM, PLD, AGCO, ABB, ALK, ALKS, DDD, ASPS, ACIW, AIXG, ALU, AMAG", "AMAG Streamlines Operations - Analyst Blog", "AMAG's Rienso Cleared in the EU - Analyst Blog", "AMAG Beats Riding on Feraheme Sales - Analyst Blog", "Allos Eyed by Spectrum Pharma - Analyst Blog", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "Revenues Decline at AMAG - Analyst Blog", "China's Slashed Growth Forecast Weighs on Stock Futures", "Allos Therapeutics Cut to Neutral - Analyst Blog", "AMAG Q4 Sales Set to Disappoint - Analyst Blog", "AMAG's Feraheme Gets Canada Nod - Analyst Blog", "Allos Continues to Outperform - Analyst Blog", "AMAG Hires Financial Advisor - Analyst Blog", "Allos Upped to Outperform - Analyst Blog", "Stocks Rally on European Debt Summit Optimism; December Crude Surges Over 2%", "Mid-Day Update: Stocks Surge, Indexes Top 1% on Europe Debt Optimism, Earnings", "Top 10 list of unusual option activity", "Options Ideas: 24 Healthcare Stocks With Bullish Options Sentiment", "4 Biotech Stocks That Could Pop", "A 'Buy' Signal for Biotech's Best Value Play", "Today's Earnings Movers: TNAV, MWW, CSTR, GMO, AXTI Higher; NR, NUVA, AMAG, OSTK, GWW Lower", "Mid-Day Update: Stocks Pare Some Early Losses; Unemployment Claims Lift Sentiment", "Options Trade of the Day: A Ratio Call Spread on AMAG Pharmaceuticals Inc.", "Iron Safety Hits AMAG Pharmaceuticals", "Looking for Value in September's Biggest Losers"], "Elapsed Time": ["MAY 19, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 6, 2020", "MAR 4, 2020", "MAR 4, 2020", "FEB 16, 2020", "JAN 19, 2020", "MAY 19, 2020", "DEC 15, 2019", "DEC 15, 2019", "NOV 1, 2019", "NOV 1, 2019", "OCT 31, 2019", "OCT 30, 2019", "OCT 30, 2019", "JAN 19, 2020", "OCT 25, 2019", "OCT 25, 2019", "OCT 25, 2019", "OCT 11, 2019", "SEP 27, 2019", "AUG 12, 2019", "AUG 9, 2019", "OCT 29, 2019", "JUN 25, 2019", "JUN 24, 2019", "JUN 24, 2019", "JUN 24, 2019", "JUN 4, 2019", "MAY 24, 2019", "MAR 13, 2019", "AUG 7, 2019", "MAR 9, 2019", "FEB 17, 2019", "FEB 8, 2019", "FEB 8, 2019", "FEB 7, 2019", "DEC 27, 2018", "DEC 16, 2018", "MAR 11, 2019", "NOV 26, 2018", "NOV 18, 2018", "NOV 3, 2018", "NOV 2, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 1, 2018", "DEC 14, 2018", "OCT 31, 2018", "OCT 29, 2018", "OCT 26, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 24, 2018", "OCT 22, 2018", "OCT 31, 2018", "SEP 27, 2018", "SEP 18, 2018", "SEP 4, 2018", "AUG 19, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUN 4, 2018", "OCT 5, 2018", "MAY 4, 2018", "MAY 1, 2018", "MAR 29, 2018", "FEB 28, 2018", "FEB 23, 2018", "FEB 18, 2018", "FEB 15, 2018", "JUN 4, 2018", "MAY 4, 2018", "MAY 1, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 5, 2018", "FEB 15, 2018", "FEB 5, 2018", "JAN 31, 2018", "JAN 23, 2018", "DEC 21, 2017", "DEC 20, 2017", "DEC 20, 2017", "NOV 3, 2017", "FEB 5, 2018", "OCT 20, 2017", "SEP 5, 2017", "SEP 1, 2017", "AUG 4, 2017", "JUL 24, 2017", "JUL 5, 2017", "JUN 2, 2017", "NOV 1, 2017", "MAY 15, 2017", "MAY 10, 2017", "MAY 4, 2017", "MAY 3, 2017", "APR 18, 2017", "APR 12, 2017", "MAR 31, 2017", "MAY 15, 2017", "MAR 22, 2017", "MAR 8, 2017", "FEB 15, 2017", "FEB 14, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 10, 2017", "MAR 30, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 8, 2017", "JAN 10, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "DEC 29, 2016", "JAN 19, 2017", "NOV 7, 2016", "OCT 13, 2016", "OCT 7, 2016", "AUG 10, 2016", "JUL 1, 2016", "JUN 12, 2016", "MAY 25, 2016", "DEC 23, 2016", "MAY 18, 2016", "MAY 4, 2016", "APR 18, 2016", "APR 15, 2016", "APR 14, 2016", "APR 14, 2016", "APR 13, 2016", "MAY 19, 2016", "APR 13, 2016", "APR 13, 2016", "APR 12, 2016", "APR 12, 2016", "APR 12, 2016", "APR 11, 2016", "APR 8, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 7, 2016", "APR 7, 2016", "APR 7, 2016", "APR 6, 2016", "APR 6, 2016", "APR 8, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 4, 2016", "APR 4, 2016", "APR 6, 2016", "APR 1, 2016", "APR 1, 2016", "MAR 31, 2016", "MAR 30, 2016", "MAR 30, 2016", "MAR 30, 2016", "MAR 29, 2016", "APR 4, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 28, 2016", "MAR 28, 2016", "MAR 28, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 29, 2016", "MAR 24, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 18, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 24, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 16, 2016", "MAR 10, 2016", "MAR 8, 2016", "MAR 7, 2016", "MAR 7, 2016", "MAR 7, 2016", "MAR 4, 2016", "MAR 4, 2016", "MAR 14, 2016", "MAR 1, 2016", "FEB 29, 2016", "FEB 29, 2016", "FEB 29, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 26, 2016", "MAR 3, 2016", "FEB 25, 2016", "FEB 25, 2016", "FEB 23, 2016", "FEB 20, 2016", "FEB 18, 2016", "JAN 14, 2016", "JAN 4, 2016", "FEB 25, 2016", "DEC 15, 2015", "NOV 24, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 13, 2015", "NOV 9, 2015", "DEC 18, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 3, 2015", "OCT 30, 2015", "OCT 30, 2015", "OCT 30, 2015", "OCT 30, 2015", "NOV 3, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 28, 2015", "OCT 30, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 21, 2015", "OCT 13, 2015", "OCT 27, 2015", "AUG 26, 2015", "AUG 21, 2015", "AUG 20, 2015", "AUG 19, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 18, 2015", "SEP 10, 2015", "AUG 26, 2015", "AUG 21, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 18, 2015", "AUG 13, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 11, 2015", "AUG 13, 2015", "AUG 11, 2015", "AUG 10, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 11, 2015", "AUG 6, 2015", "AUG 5, 2015", "AUG 4, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 31, 2015", "AUG 6, 2015", "JUL 31, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 31, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 28, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 23, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 22, 2015", "JUL 20, 2015", "JUL 20, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 17, 2015", "JUL 21, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 15, 2015", "JUL 15, 2015", "JUL 15, 2015", "JUL 16, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 13, 2015", "JUL 13, 2015", "JUL 13, 2015", "JUL 15, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 10, 2015", "JUL 13, 2015", "JUL 9, 2015", "JUL 8, 2015", "JUL 8, 2015", "JUL 8, 2015", "JUL 7, 2015", "JUL 7, 2015", "JUL 7, 2015", "JUL 9, 2015", "JUL 9, 2015", "JUN 1, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 6, 2015", "MAY 4, 2015", "APR 14, 2015", "JUN 30, 2015", "MAR 12, 2015", "FEB 27, 2015", "FEB 27, 2015", "FEB 10, 2015", "FEB 6, 2015", "FEB 5, 2015", "FEB 5, 2015", "APR 1, 2015", "FEB 5, 2015", "FEB 4, 2015", "FEB 3, 2015", "FEB 2, 2015", "JAN 30, 2015", "JAN 30, 2015", "JAN 29, 2015", "FEB 5, 2015", "JAN 28, 2015", "JAN 23, 2015", "JAN 22, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 29, 2015", "JAN 19, 2015", "JAN 19, 2015", "JAN 19, 2015", "JAN 16, 2015", "JAN 16, 2015", "JAN 16, 2015", "JAN 15, 2015", "JAN 20, 2015", "JAN 15, 2015", "JAN 15, 2015", "JAN 15, 2015", "JAN 15, 2015", "JAN 14, 2015", "JAN 14, 2015", "JAN 14, 2015", "JAN 15, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 8, 2015", "JAN 12, 2015", "JAN 8, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 8, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 5, 2015", "JAN 5, 2015", "JAN 2, 2015", "JAN 2, 2015", "DEC 31, 2014", "JAN 6, 2015", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 11, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 30, 2014", "DEC 4, 2014", "DEC 3, 2014", "DEC 3, 2014", "DEC 2, 2014", "DEC 1, 2014", "NOV 28, 2014", "NOV 28, 2014", "DEC 4, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 28, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 26, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 20, 2014", "NOV 20, 2014", "NOV 24, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 18, 2014", "NOV 18, 2014", "NOV 18, 2014", "NOV 19, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 14, 2014", "NOV 13, 2014", "NOV 18, 2014", "NOV 13, 2014", "NOV 12, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 13, 2014", "NOV 10, 2014", "NOV 7, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 10, 2014", "NOV 10, 2014", "NOV 5, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 5, 2014", "NOV 3, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 29, 2014", "OCT 29, 2014", "NOV 3, 2014", "NOV 3, 2014", "OCT 28, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 29, 2014", "OCT 2, 2014", "SEP 30, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 5, 2014", "JUL 30, 2014", "JUL 29, 2014", "OCT 23, 2014", "JUL 28, 2014", "JUL 21, 2014", "JUL 2, 2014", "JUN 24, 2014", "APR 25, 2014", "FEB 7, 2014", "JAN 23, 2014", "JUL 29, 2014", "JAN 9, 2014", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "JAN 14, 2014", "DEC 4, 2013", "DEC 4, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 2, 2013", "DEC 4, 2013", "DEC 2, 2013", "DEC 2, 2013", "NOV 29, 2013", "NOV 29, 2013", "NOV 26, 2013", "NOV 25, 2013", "NOV 22, 2013", "DEC 2, 2013", "NOV 21, 2013", "NOV 21, 2013", "NOV 20, 2013", "NOV 20, 2013", "NOV 19, 2013", "NOV 18, 2013", "NOV 18, 2013", "NOV 22, 2013", "NOV 15, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 13, 2013", "NOV 12, 2013", "NOV 12, 2013", "NOV 18, 2013", "NOV 12, 2013", "NOV 12, 2013", "NOV 11, 2013", "NOV 11, 2013", "NOV 11, 2013", "NOV 11, 2013", "NOV 11, 2013", "NOV 12, 2013", "NOV 8, 2013", "NOV 7, 2013", "NOV 7, 2013", "NOV 7, 2013", "NOV 7, 2013", "NOV 6, 2013", "NOV 6, 2013", "NOV 8, 2013", "NOV 8, 2013", "NOV 5, 2013", "NOV 5, 2013", "NOV 5, 2013", "NOV 4, 2013", "NOV 1, 2013", "NOV 1, 2013", "NOV 6, 2013", "OCT 31, 2013", "OCT 31, 2013", "OCT 30, 2013", "OCT 30, 2013", "OCT 30, 2013", "OCT 29, 2013", "OCT 29, 2013", "NOV 1, 2013", "OCT 22, 2013", "OCT 21, 2013", "OCT 21, 2013", "OCT 21, 2013", "OCT 18, 2013", "OCT 18, 2013", "OCT 18, 2013", "OCT 24, 2013", "OCT 17, 2013", "OCT 17, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 16, 2013", "OCT 15, 2013", "OCT 17, 2013", "AUG 9, 2013", "AUG 6, 2013", "AUG 2, 2013", "JUN 10, 2013", "MAY 22, 2013", "MAY 22, 2013", "APR 24, 2013", "SEP 26, 2013", "MAR 11, 2013", "MAR 4, 2013", "JAN 7, 2013", "DEC 27, 2012", "DEC 11, 2012", "NOV 12, 2012", "NOV 5, 2012", "MAR 18, 2013", "AUG 1, 2012", "JUL 27, 2012", "JUL 25, 2012", "JUN 26, 2012", "JUN 25, 2012", "MAY 2, 2012", "APR 9, 2012", "OCT 10, 2012", "MAR 8, 2012", "MAR 5, 2012", "JAN 12, 2012", "JAN 11, 2012", "DEC 15, 2011", "NOV 25, 2011", "NOV 18, 2011", "MAR 22, 2012", "OCT 21, 2011", "OCT 21, 2011", "OCT 7, 2011", "JUN 7, 2011", "MAY 18, 2011", "NOV 30, 2010", "OCT 29, 2010", "NOV 17, 2011", "SEP 27, 2010", "FEB 4, 2010", "OCT 4, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/adct-closes-ipo-aldx-to-provide-covid-19-update-rwlk-to-focus-on-telehealth-2020-05-19", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc-amag-q1-2020-earnings-call-transcript-2020-05-11", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cellect-biotechnology-under-armour-amc-entertainment-2020-05", "https://www.nasdaq.com/articles/should-you-buy-this-stock-that-makes-viagra-for-women-2020-05-06", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-struggled-again-in-q4-2020-03-04", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc-amag-q4-2019-earnings-call-transcript-2020-03-04", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joseph-piotroski-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/adct-closes-ipo-aldx-to-provide-covid-19-update-rwlk-to-focus-on-telehealth-2020-05-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joseph-piotroski-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc-amag-q3-2019-earnings-call-transcript-2019-11-01", "https://www.nasdaq.com/articles/amag-pharmaceuticals-q3-results-overshadowed-by-ominous-fda-panel-recommendation-2019-11", "https://www.nasdaq.com/articles/top-5-losers-in-healthcare-sector-cycn-amag-elgx...-2019-10-31", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-is-tanking-today-2019-10-30", "https://www.nasdaq.com/articles/its-9-7-for-withdrawal-of-makena-roche-spark-deal-delayed-again-mrk-on-watch-2019-10-30", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-joseph-piotroski-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-25-2019%3A-cgixidxgamagrmduhs-2019-10-25", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-tap-amag-rp-2019-10-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-25-2019%3A-amagrmduhs-2019-10-25", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-anet-lyft-amag-2019-10-11", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-october-2019-2019-09-27", "https://www.nasdaq.com/articles/monday-8-12-insider-buying-report%3A-amag-nflx-2019-08-12", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc-amag-q2-2019-earnings-call-transcript-2019-08-09", "https://www.nasdaq.com/articles/fda-committee-recommends-removing-makena-drug-for-preventing-premature-births-2019-10-29", "https://www.nasdaq.com/articles/why-palatin-technologies-stock-dropped-as-much-as-21.5-today-2019-06-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-24-2019%3A-krysptnamagmesobmycelg-2019-06-24", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-24-2019%3A-ptnamagmesobmycelg-2019-06-24", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-24-2019%3A-ptn-amag-meso-bmy-celg-jnj-pfe-abt-mrk-amgn-2019", "https://www.nasdaq.com/articles/3-drug-stocks-could-win-key-fda-approvals-june-2019-06-04", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-june-2019-2019-05-24", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regn-gets-fda-nod-for-dupixent-other-pipeline-news-2019-03-13", "https://www.nasdaq.com/articles/whats-behind-amag-pharmaceuticals-horrible-q2-results-2019-08-07", "https://www.nasdaq.com/articles/why-is-amag-pharmaceuticals-amag-down-24.5-since-last-earnings-report-2019-03-09", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-2172019-2019-02-17", "https://www.nasdaq.com/articles/amag-q4-loss-narrower-than-expected-revenues-lag-estimates-2019-02-08", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-q4-2018-earnings-conference-call-transcript-2019-02-08", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-reports-q4-loss-misses-revenue-estimates-2019-02-07", "https://www.nasdaq.com/articles/amag-up-nearly-10-in-a-year-on-label-expansion-acquisitions-2018-12-27", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-12162018-2018-12-16", "https://www.nasdaq.com/articles/amags-stock-down-as-pregnancy-drug-fails-in-prolong-study-2019-03-11", "https://www.nasdaq.com/articles/amags-label-expansion-of-lead-products-raises-share-price-2018-11-26", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-11182018-2018-11-18", "https://www.nasdaq.com/articles/validea-kenneth-fisher-strategy-daily-upgrade-report-1132018-2018-11-03", "https://www.nasdaq.com/articles/amag-posts-wider-than-expected-q3-loss-beats-on-revenues-2018-11-02", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc-amag-q3-2018-earnings-conference-call-transcript-2018-11-01", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-reports-q3-loss-tops-revenue-estimates-2018-11-01", "https://www.nasdaq.com/articles/heres-why-amag-pharmaceuticals-tumbled-127-today-2018-11-01", "https://www.nasdaq.com/articles/amag-to-acquire-ciraparantag-maker-perosphere-pharmaceuticals-2018-12-14", "https://www.nasdaq.com/articles/will-cigna-ci-q3-earnings-gain-on-revenue-growth-2018-10-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-allergan-regeneron-pharmaceuticals-amgen-alnylam", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings-2018-10-26", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-q3-earnings-preview%3A-what-to-watch-ahead-of-the-release-2018-10", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-zoetis-zts-this-earnings-season-2018-10-25", "https://www.nasdaq.com/articles/commit-buy-amag-pharmaceuticals-17-earn-105-annualized-using-options-2018-10-24", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-whats-in-the-cards-2018-10-22", "https://www.nasdaq.com/articles/whats-in-the-cards-for-novavax-nvax-this-earnings-season-2018-10-31", "https://www.nasdaq.com/articles/amag-in-licenses-global-rights-to-orphan-drug-candidate-2018-09-27", "https://www.nasdaq.com/articles/amag-pharmaceuticals-becomes-oversold-2018-09-18", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-amag-pharmaceuticals-amag-stock-2018-09-04", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-joseph-piotroski-8192018-2018-08-19", "https://www.nasdaq.com/articles/health-care-sector-update-06152018-rdytevaamagbgne-2018-06-15", "https://www.nasdaq.com/articles/health-care-sector-update-06152018-tevaamagbgne-2018-06-15", "https://www.nasdaq.com/articles/health-care-sector-update-06042018-dcphloxoptnamagvxrt-2018-06-04", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-october-5th-2018-10-05", "https://www.nasdaq.com/articles/amag-pharma-amag-q1-loss-wider-than-expected-lifts-view-2018-05-04", "https://www.nasdaq.com/articles/teva-teva-to-report-q1-earnings%3A-whats-in-the-cards-2018-05-01", "https://www.nasdaq.com/articles/amag-pharma-amag-down-10.6-since-earnings-report%3A-can-it-rebound-2018-03-29", "https://www.nasdaq.com/articles/amag-pharma-amag-beats-on-q4-earnings-misses-on-revenues-2018-02-28", "https://www.nasdaq.com/articles/these-2-biotech-stocks-are-soaring-can-they-keep-it-2018-02-23", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-2182018-2018-02-18", "https://www.nasdaq.com/articles/mid-day-market-update-solaredge-technologies-gains-following-q4-earnings-beat-avid", "https://www.nasdaq.com/articles/health-care-sector-update-06042018-loxoptnamagvxrt-2018-06-04", "https://www.nasdaq.com/articles/amag-pharma-amag-q1-loss-wider-than-expected-lifts-view-2018-05-04", "https://www.nasdaq.com/articles/teva-teva-to-report-q1-earnings%3A-whats-in-the-cards-2018-05-01", "https://www.nasdaq.com/articles/biotech-stock-pops-30-fda-nod-slamming-door-woes-2018-02-15", "https://www.nasdaq.com/articles/health-care-sector-update-02152018-amagatrscdmoztsarwr-2018-02-15", "https://www.nasdaq.com/articles/mid-afternoon-market-update-build-bear-surges-upbeat-earnings-inpixon-shares-drop-2018-02", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-inc-amag-shares-are-skyrocketing-today-2018-02-15", "https://www.nasdaq.com/articles/health-care-sector-update-02052018-jnj-pfe-abt-mrk-amgn-sppi-capr-amag-cric-bmy-mgen-2018", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-inc-and-antares-pharma-inc-are-soaring-today-2018-02-15", "https://www.nasdaq.com/articles/health-care-sector-update-02052018-sppiamagctic-2018-02-05", "https://www.nasdaq.com/articles/vertex-vrtx-other-drug-stocks-fda-catalysts-february-2018-01-31", "https://www.nasdaq.com/articles/commit-purchase-amag-pharmaceuticals-12-earn-439-annualized-using-options-2018-01-23", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-ftxh-2017-12-21", "https://www.nasdaq.com/articles/therapeuticsmd-falls-despite-acceptance-of-nda%3A-heres-why-2017-12-20", "https://www.nasdaq.com/articles/health-care-sector-update-12202017-atosamagapdneglt-2017-12-20", "https://www.nasdaq.com/articles/amag-pharmas-amag-q3-earnings-beat-lowers-17-outlook-2017-11-03", "https://www.nasdaq.com/articles/health-care-sector-update-02052018-mgensppiamagctic-2018-02-05", "https://www.nasdaq.com/articles/mid-day-market-update-dow-surges-over-100-points-durect-shares-plummet-2017-10-20", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-down-6.6-since-earnings-report%3A-can-it-rebound-2017-09-05", "https://www.nasdaq.com/articles/amags-filing-for-ferahemes-label-expansion-accepted-by-fda-2017-09-01", "https://www.nasdaq.com/articles/amag-pharma-amag-incurs-narrower-than-expected-loss-in-q2-2017-08-04", "https://www.nasdaq.com/articles/spark-therapeutics-once-worth-a-look%3A-stock-gains-5.7-2017-07-24", "https://www.nasdaq.com/articles/amag-pharmaceuticals-focuses-on-product-development-buyouts-2017-07-05", "https://www.nasdaq.com/articles/why-is-amag-pharmaceuticals-amag-down-15.6-since-the-last-earnings-report-2017-06-02", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-inc-substantial-upside-misunderstood-drug-maker-2017-11-01", "https://www.nasdaq.com/articles/bear-day-amag-pharmaceuticals-amag-2017-05-15", "https://www.nasdaq.com/articles/what-makes-amag-pharmaceuticals-amag-a-strong-sell-2017-05-10", "https://www.nasdaq.com/articles/after-hours-most-active-may-4-2017-bac-jnpr-pfe-gm-fcx-cf-sbux-cmcsa-yhoo-qcom-stx-amag", "https://www.nasdaq.com/articles/amag-pharma-amag-incurs-loss-in-q1-revenues-rise-y-y-2017-05-03", "https://www.nasdaq.com/articles/amag-files-for-fda-approval-of-subcutaneous-form-of-makena-2017-04-18", "https://www.nasdaq.com/articles/therapeuticsmd-falls-on-likely-delay-in-tx-004hr-approval-2017-04-12", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ptc-covanta-holding-etsy-incyte-and-amag-pharmaceuticals", "https://www.nasdaq.com/articles/alpha-omega-semiconductor-amag-pharmaceuticals-and-trade-desk-highlighted-as-zacks-bull", "https://www.nasdaq.com/articles/billionaires-worst-healthcare-stock-picks-2017-so-far-2017-03-22", "https://www.nasdaq.com/articles/heres-why-natera-inc-tumbling-today-2017-03-08", "https://www.nasdaq.com/articles/amag-pharma-amag-incurs-loss-in-q4-revenues-lag-estimates-2017-02-15", "https://www.nasdaq.com/articles/earnings-reaction-history-amag-pharmaceuticals-inc-200-follow-through-indicator-51", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2017-02-10", "https://www.nasdaq.com/articles/perrigo-company-prgo-q4-earnings%3A-disappointment-in-store-2017-02-10", "https://www.nasdaq.com/articles/alexion-alxn-q4-earnings%3A-can-the-stock-pull-a-surprise-2017-02-10", "https://www.nasdaq.com/articles/5-toxic-stocks-to-get-rid-of-or-play-short-to-make-gains-2017-03-30", "https://www.nasdaq.com/articles/gilead-sciences-gild-q4-earnings%3A-whats-in-the-cards-2017-02-03", "https://www.nasdaq.com/articles/wall-street-poised-rally-after-upbeat-jobs-data-2017-02-03", "https://www.nasdaq.com/articles/us-futures-modestly-higher-ahead-jobs-data-2017-02-03", "https://www.nasdaq.com/articles/amag-down-despite-positive-data-on-makena-auto-injector-2017-02-03", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-q1-earnings%3A-whats-in-store-2017-02-02", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-facebook-beats-q4-estimates-2017-02-02", "https://www.nasdaq.com/articles/heres-why-amag-pharmaceuticals-falling-today-2017-02-02", "https://www.nasdaq.com/articles/teva-teva-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-08", "https://www.nasdaq.com/articles/amag-palatin-ink-deal-to-focus-on-female-sexual-disorder-2017-01-10", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-inc-falling-today-2017-01-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-january-9th-2017-01-09", "https://www.nasdaq.com/articles/health-care-sector-update-01092017-ariaetrmamag-2017-01-09", "https://www.nasdaq.com/articles/mid-afternoon-market-update-ariad-pharmaceuticals-surges-acquisition-news-stage-stores", "https://www.nasdaq.com/articles/health-care-sector-update-01092017-ptx-etrm-amag-sny-ptn-2017-01-09", "https://www.nasdaq.com/articles/commit-purchase-amag-pharmaceuticals-26-earn-121-annualized-using-options-2016-12-29", "https://www.nasdaq.com/articles/is-amag-pharmaceuticals-amag-a-good-value-pick-2017-01-19", "https://www.nasdaq.com/articles/amag-pharma-amag-q3-earnings-up-y-y-revenues-beat-2016-11-07", "https://www.nasdaq.com/articles/amag-issues-encouraging-updates-on-makena-feraheme-2016-10-13", "https://www.nasdaq.com/articles/steven-cohen-increases-position-dynavax-2016-10-07", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-inc-tanking-today-2016-08-10", "https://www.nasdaq.com/articles/10-biotech-and-specialty-pharma-bargains-do-you-have-guts-speculate-2016-07-01", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-inc-plunged-192-may-2016-06-12", "https://www.nasdaq.com/articles/should-you-get-rid-of-amag-pharmaceuticals-amag-now-2016-05-25", "https://www.nasdaq.com/articles/where-will-amag-pharmaceuticals-be-1-year-now-2016-12-23", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-may-18th-2016-05-18", "https://www.nasdaq.com/articles/amag-amag-q1-earnings-beat-estimates-keeps-2016-view-2016-05-04", "https://www.nasdaq.com/articles/gilead-presents-multiple-hcv-and-hbv-data-at-liver-congress-2016-04-18", "https://www.nasdaq.com/articles/synta-stock-up-on-merger-deal-with-madrigal-pharmaceuticals-2016-04-15", "https://www.nasdaq.com/articles/merck-offers-positive-data-from-comparative-trial-on-zepatier-2016-04-14", "https://www.nasdaq.com/articles/intrexon-xon-gains-following-deals-with-two-startups-2016-04-14", "https://www.nasdaq.com/articles/repros-reveals-positive-data-on-proellex-for-uterine-fibroids-2016-04-13", "https://www.nasdaq.com/articles/new-strong-sell-stocks-may-19th-2016-05-19", "https://www.nasdaq.com/articles/horizon-pharma-plunges-on-bleak-q1-and-1h16-guidance-2016-04-13", "https://www.nasdaq.com/articles/arena-arna-gains-pain-drug-positive-in-early-stage-study-2016-04-13", "https://www.nasdaq.com/articles/gw-pharmaceuticals-begins-another-phase-iii-epidiolex-trial-2016-04-12", "https://www.nasdaq.com/articles/regeneron-intellia-strike-deal-for-crispr-cas-platform-2016-04-12", "https://www.nasdaq.com/articles/trovagene-inks-strategic-partnership-with-stratose-stock-up-2016-04-12", "https://www.nasdaq.com/articles/vivus-vvus-upgraded-to-hold-on-strong-fundamentals-2016-04-11", "https://www.nasdaq.com/articles/medivation-astellas-xtandi-gets-chmp-nod-to-include-data-2016-04-08", "https://www.nasdaq.com/articles/valeant-vrx-receives-notice-of-default%3A-stock-in-trouble-2016-04-13", "https://www.nasdaq.com/articles/horizon-pharma-plunges-on-bleak-q1-and-1h16-guidance-2016-04-13", "https://www.nasdaq.com/articles/illumina-unveils-basespace-suite-boosts-precision-medicine-2016-04-08", "https://www.nasdaq.com/articles/incyte-buys-rights-to-jakafi-for-graft-versus-host-disease-2016-04-07", "https://www.nasdaq.com/articles/4-top-ranked-healthcare-stocks-that-surged-last-session-2016-04-07", "https://www.nasdaq.com/articles/4-value-stocks-that-suggest-earnings-growth-of-50-or-more-2016-04-07", "https://www.nasdaq.com/articles/pfizer-merck-kgaa-initiate-avelumab-inlyta-combo-study-2016-04-06", "https://www.nasdaq.com/articles/ironwood-slumps-halts-development-of-gastroparesis-drug-2016-04-06", "https://www.nasdaq.com/articles/angiodynamics-tops-q3-earnings-sales-fy16-view-pruned-2016-04-08", "https://www.nasdaq.com/articles/abbvie-up-wins-chmp-backing-for-humiras-expanded-use-2016-04-05", "https://www.nasdaq.com/articles/intrexon-ties-up-with-external-investors-for-type-i-diabetes-2016-04-05", "https://www.nasdaq.com/articles/4-great-stocks-ride-ibb-rebound-2016-04-05", "https://www.nasdaq.com/articles/baxalta-adynovate-gets-japanese-approval-for-hemophilia-a-2016-04-05", "https://www.nasdaq.com/articles/gilead-descovy-wins-fda-nod-to-buy-nimbus-liver-program-2016-04-05", "https://www.nasdaq.com/articles/glaxos-gsk-strimvelis-gets-chmp-nod-for-rare-disorder-2016-04-04", "https://www.nasdaq.com/articles/bristol-myers-gets-chmp-backing-for-opdivos-expanded-use-2016-04-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-edwards-lifesciences-pra-health-sciences-gilead", "https://www.nasdaq.com/articles/dr.-reddys-acquires-anticancer-drug-rights-from-eisai-2016-04-01", "https://www.nasdaq.com/articles/gilead-seeks-approval-for-tenofovir-alafenamide-in-japan-2016-04-01", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-vrx-still-a-strong-sell-stock-2016-03-31", "https://www.nasdaq.com/articles/inovio-ino-offers-update-on-development-plan-for-ino-3112-2016-03-30", "https://www.nasdaq.com/articles/3-biotech-stocks-that-make-the-grade-for-investors-2016-03-30", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-looks-good%3A-stock-adds-5-2016-03-30", "https://www.nasdaq.com/articles/pumas-pbyi-filing-for-breast-cancer-drug-neratinib-delayed-2016-03-29", "https://www.nasdaq.com/articles/regeneron-sanofi-up-eczema-drug-tops-phase-iii-studies-2016-04-04", "https://www.nasdaq.com/articles/apricus-hits-52-week-low-on-unfavorable-fispemifene-data-2016-03-29", "https://www.nasdaq.com/articles/alder-aldr-surges-on-positive-data-on-migraine-candidate-2016-03-29", "https://www.nasdaq.com/articles/biomarin-bmrn-bmn-270-gets-orphan-drug-status-in-eu-2016-03-28", "https://www.nasdaq.com/articles/portola-hits-52-week-low-on-unfavorable-betrixaban-data-2016-03-28", "https://www.nasdaq.com/articles/dr-reddys-collaborates-with-xenoport-for-psoriasis-drug-2016-03-28", "https://www.nasdaq.com/articles/pfizers-revised-filing-for-xeljanz-accepted-for-review-in-eu-2016-03-24", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-phase-iii-data-on-praluent-2016-03-24", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-kanuma-gains-approval-in-japan-2016-03-29", "https://www.nasdaq.com/articles/bristol-myers-to-buy-padlock-focus-on-autoimmune-diseases-2016-03-24", "https://www.nasdaq.com/articles/biomarin-bmrn-down-on-phase-iii-data-on-pegvaliase-2016-03-22", "https://www.nasdaq.com/articles/bio-techne-buys-zephyrus-boosts-protein-platforms-division-2016-03-22", "https://www.nasdaq.com/articles/acorda-gets-favorable-court-ruling-in-ampyra-patent-lawsuit-2016-03-22", "https://www.nasdaq.com/articles/bayers-kovaltry-gets-approval-in-the-u.s.-for-hemophilia-a-2016-03-18", "https://www.nasdaq.com/articles/amag-initiates-enrolment-in-phase-iii-study-on-feraheme-2016-03-17", "https://www.nasdaq.com/articles/orexigen-buys-u.s.-rights-to-contrave-inks-deal-in-the-eu-2016-03-16", "https://www.nasdaq.com/articles/astrazenecas-heart-drug-brilinta-disappoints-in-stroke-study-2016-03-24", "https://www.nasdaq.com/articles/5-unbeatable-stocks-to-brave-the-market-mayhem-2016-03-15", "https://www.nasdaq.com/articles/repros-incurs-narrower-than-expected-loss-in-q4-shares-up-2016-03-15", "https://www.nasdaq.com/articles/inovio-ino-4q-loss-wider-than-expected-pipeline-in-focus-2016-03-15", "https://www.nasdaq.com/articles/gw-pharmaceuticals-skyrockets-on-favorable-epilepsy-data-2016-03-15", "https://www.nasdaq.com/articles/mannkind-posts-wider-than-expected-loss-afrezza-in-focus-2016-03-15", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-sarilumab-phase-iii-data-2016-03-14", "https://www.nasdaq.com/articles/gileads-zydelig-under-eu-review-amid-safety-concerns-2016-03-14", "https://www.nasdaq.com/articles/eli-lilly-down-alters-primary-endpoint-of-solanezumab-2016-03-16", "https://www.nasdaq.com/articles/spectrum-sppi-incurs-narrower-than-expected-loss-in-q4-2016-03-10", "https://www.nasdaq.com/articles/celldex-advised-to-discontinue-phase-iii-study-on-rintega-2016-03-08", "https://www.nasdaq.com/articles/eli-lillys-ixekizumab-positive-in-plaque-psoriasis-studies-2016-03-07", "https://www.nasdaq.com/articles/novo-nordisk-victoza-lowers-cardiovascular-risk-per-study-2016-03-07", "https://www.nasdaq.com/articles/qiagen%3A-molecular-diagnostics-a-drag-currency-woes-persist-2016-03-07", "https://www.nasdaq.com/articles/avalanche-aavl-reports-wider-than-expected-loss-in-q4-2016-03-04", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-amag-pharmaceuticals-amag%3A-time-to-buy-2016-03-04", "https://www.nasdaq.com/articles/pfizers-lung-cancer-drug-xalkori-label-expanded-in-u.s.-2016-03-14", "https://www.nasdaq.com/articles/horizon-hznp-misses-on-q4-earnings-beats-on-revenues-2016-03-01", "https://www.nasdaq.com/articles/emergent-ebs-beats-on-q4-earnings-revenues-up-y-y-2016-02-29", "https://www.nasdaq.com/articles/qlt-qlti-reports-narrower-than-expected-loss-in-q4-2016-02-29", "https://www.nasdaq.com/articles/bayer-bayry-q4-earnings-lag-estimates-gives-2016-view-2016-02-29", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-amag-pharmaceuticals-amag-2016-02-26", "https://www.nasdaq.com/articles/biomarin-incurs-loss-in-q4-misses-estimates-gives-16-view-2016-02-26", "https://www.nasdaq.com/articles/alkermes-q4-loss-narrower-than-expected-updates-pipeline-2016-02-26", "https://www.nasdaq.com/articles/biomarin-bmrn-presents-positive-data-on-cerliponase-alfa-2016-03-03", "https://www.nasdaq.com/articles/bull-day-amag-pharma-amag-2016-02-25", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-amag-pharmaceuticals-amag-stock-2016-02-25", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-february-23rd-2016-02-23", "https://www.nasdaq.com/articles/last-weeks-best-healthcare-etf-2016-02-20", "https://www.nasdaq.com/articles/amag-q4-earnings-revenues-up-y-y-gives-2016-outlook-2016-02-18", "https://www.nasdaq.com/articles/3-value-stocks-near-52-week-lows-worth-buying-2016-01-14", "https://www.nasdaq.com/articles/health-care-sector-update-01042016-amagunismymx-2016-01-04", "https://www.nasdaq.com/articles/amag-pharmaceuticals-oil-states-international-usa-compression-mcdermott-international", "https://www.nasdaq.com/articles/akebia-up-on-mitsubishi-tanabe-pharma-deal-for-vadadustat-2015-12-15", "https://www.nasdaq.com/articles/amag-responds-to-fdas-crl-for-single-dose-vial-of-makena-2015-11-24", "https://www.nasdaq.com/articles/health-care-sector-update-11192015-lly-mrk-athx-amag-2015-11-19", "https://www.nasdaq.com/articles/amag-receives-another-crl-for-single-dose-vial-of-makena-2015-11-19", "https://www.nasdaq.com/articles/mid-afternoon-market-update-kirklands-drops-downbeat-earnings-perry-ellis-shares-spike", "https://www.nasdaq.com/articles/weakness-seen-in-amag-pharmaceuticals-amag-estimates%3A-should-you-stay-away-2015-11-13", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-november-9th-2015-11-09", "https://www.nasdaq.com/articles/7-best-cheap-stocks-buy-2016-2015-12-18", "https://www.nasdaq.com/articles/health-care-sector-update-11032015-amag-mdco-isis-2015-11-03", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-rises-125-points-retailmenot-shares-climb-earnings-beat", "https://www.nasdaq.com/articles/why-amag-phamaceuticals-shares-are-crashing-today-2015-11-03", "https://www.nasdaq.com/articles/qlt-qlti-reports-narrower-than-expected-loss-in-q3-2015-10-30", "https://www.nasdaq.com/articles/bayer-bayry-q3-revenues-up-y-y-2015-view-adjusted-2015-10-30", "https://www.nasdaq.com/articles/gnc-holdings-earnings-revenues-lag-franchise-unit-strong-2015-10-30", "https://www.nasdaq.com/articles/keryx-q3-loss-wider-than-expected-auryxia-in-focus-2015-10-30", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-rise-taser-shares-drop-downbeat-earnings-2015-11-03", "https://www.nasdaq.com/articles/qiagen-misses-on-q3-earnings-and-revenues-liquidity-strong-2015-10-29", "https://www.nasdaq.com/articles/affymetrix-beats-q3-earnings-lags-sales-margins-view-up-2015-10-29", "https://www.nasdaq.com/articles/vertex-vrtx-posts-narrower-q3-loss-ups-kalydeco-view-2015-10-29", "https://www.nasdaq.com/articles/amag-to-initiate-head-to-head-phase-iii-study-on-feraheme-2015-10-29", "https://www.nasdaq.com/articles/theravances-q3-loss-wider-than-expected-revenues-miss-2015-10-29", "https://www.nasdaq.com/articles/immunogen-imgn-reports-wider-than-expected-loss-in-q1-2015-10-28", "https://www.nasdaq.com/articles/biomarins-q3-loss-narrower-than-expected-outlook-revised-2015-10-30", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-what-to-expect-2015-10-27", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-iii-on-apaziquone-under-spa-2015-10-27", "https://www.nasdaq.com/articles/can-bristol-myers-bmy-sustain-earnings-momentum-in-q3-2015-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-gilead-gild-this-earnings-season-2015-10-23", "https://www.nasdaq.com/articles/baxter-international-bax-q3-earnings%3A-surprise-in-store-2015-10-23", "https://www.nasdaq.com/articles/keryx-to-raise-%24125m-through-private-placement-of-notes-2015-10-21", "https://www.nasdaq.com/articles/3-biotech-stocks-astonishingly-low-pe-ratios-2015-10-13", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-october-27th-2015-10-27", "https://www.nasdaq.com/articles/jj-to-sell-sugar-substitute-splenda-to-heartland-food-2015-08-26", "https://www.nasdaq.com/articles/raptor-rptp-to-buy-quinsair-boost-rare-disease-portfolio-2015-08-21", "https://www.nasdaq.com/articles/vicals-antifungal-candidate-vl-2397-receives-qidp-status-2015-08-20", "https://www.nasdaq.com/articles/mercks-keytruda-under-fda-review-for-first-line-melanoma-2015-08-19", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-in-focus%3A-stock-soars-45.3-2015-08-18", "https://www.nasdaq.com/articles/should-amag-pharmaceuticals-amag-be-on-your-radar-now-2015-08-18", "https://www.nasdaq.com/articles/biolinerx-up-on-phase-iib-study-initiation-on-leukemia-drug-2015-08-18", "https://www.nasdaq.com/articles/akebia-akba-skyrockets-on-encouraging-phase-ii-data-2015-09-10", "https://www.nasdaq.com/articles/jj-to-sell-sugar-substitute-splenda-to-heartland-food-2015-08-26", "https://www.nasdaq.com/articles/raptor-rptp-to-buy-quinsair-boost-rare-disease-portfolio-2015-08-21", "https://www.nasdaq.com/articles/acceleron-pharma-xlrn-moves-13.3-higher-in-session-2015-08-14", "https://www.nasdaq.com/articles/emergent-biosolutions-gets-%2444m-cdc-contract-for-vigiv-2015-08-14", "https://www.nasdaq.com/articles/myriad%3A-medicare-coverage-for-prolaris-prostrate-cancer-test-2015-08-14", "https://www.nasdaq.com/articles/integras-acquisitions-to-buoy-growth-in-15-currency-woes-stay-2015-08-14", "https://www.nasdaq.com/articles/biodeliverys-new-onsolis-formulation-gains-fda-approval-2015-08-14", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-label-expanded-in-the-u.s.-2015-08-18", "https://www.nasdaq.com/articles/abbvie-roches-leukemia-drug-hits-phase-ii-primary-endpoint-2015-08-13", "https://www.nasdaq.com/articles/myriad-genetics-posts-in-line-earnings-in-q4-margins-suffer-2015-08-12", "https://www.nasdaq.com/articles/novavax-nvax-shows-strength%3A-stock-moves-up-24.1-2015-08-12", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-catches-eye%3A-stock-up-5.8-2015-08-12", "https://www.nasdaq.com/articles/pluristem-psti-provides-update-on-plx-pad-cells-in-japan-2015-08-12", "https://www.nasdaq.com/articles/bioscrips-strategic-plans-offer-hope-margin-concerns-stay-2015-08-12", "https://www.nasdaq.com/articles/mannkind-mnkd-reports-narrower-than-expected-q2-loss-2015-08-11", "https://www.nasdaq.com/articles/vivus-inc.-vvus-in-focus%3A-stock-jumps-5.4-2015-08-13", "https://www.nasdaq.com/articles/biodelivery-incurs-wider-loss-in-q2-revenues-fall-y-y-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/collegiums-xtampza-to-be-reviewed-by-fda-advisory-panels-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/emergent-biosolutions-tops-on-q2-earnings-plans-spin-off-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/alnylams-q2-loss-wider-than-expected-revenues-fall-short-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/use-options-chance-buy-amag-18-discount-2015-08-06", "https://www.nasdaq.com/articles/genomic-health-q2-loss-wider-than-expected-tests-ramp-up-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/nektar-q2-loss-wider-than-expected-outlook-maintained-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/repros-incurs-narrower-y-y-loss-in-q2-pipeline-in-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/osiris-therapeutics-q2-earnings-revenues-grow-yy-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/incyte-q2-loss-narrower-than-expected-ups-jakafi-outlook-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/biomarin-q2-loss-narrower-than-expected-maintains-outlook-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/vivus-vvus-q2-loss-narrower-restructuring-announced-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/qiagen-qgen-beats-q2-earnings-revenues-keeps-15-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/amgen-beats-q2-earnings-revenues-raises-outlook-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/tevas-q2-earnings-revenues-beat-expectations-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/surmodics-srdx-beats-on-q3-earnings-improves-outlook-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/acorda-2q-earnings-revenues-top-ampyra-focus-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/vertex-posts-wider-yy-loss-raises-kalydeco-outlook-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-amag-might-be-a-diamond-in-the-rough-tale-of-the-tape-2015-07-30", "https://www.nasdaq.com/articles/theravances-q2-loss-wider-than-expected-revenues-miss-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/cytori-therapeutics-cytx-jumps%3A-stock-moves-up-10-tale-of-the-tape-2015-07-29", "https://www.nasdaq.com/articles/sanofi-regeneron-enter-immuno-oncology-collaboration-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-jumps%3A-stock-gains-9.5-tale-of-the-tape-2015-07-28", "https://www.nasdaq.com/articles/alkermes-reports-wider-q2-loss-increases-guidance-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/is-perkinelmer-pki-poised-to-beat-q2-earnings-estimates-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/will-varian-medicals-var-q3-earnings-impress-investors-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-7.6-tale-of-the-tape-2015-07-27", "https://www.nasdaq.com/articles/biogen-tops-q2-earnings-cuts-view-tecfidera-issues-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/abbvie-tops-earnings-misses-revenues-maintains-view-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/xoma-crashes-after-gevokizumab-misses-primary-endpoint-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/eli-lilly-biogen-present-data-at-alzheimers-association-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/teva-to-buy-allergans-generics-business-for-%2440.5b-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/mercks-anti-pd-1-therapy-melanoma-drug-gets-eu-nod-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/bristol-myers-beats-on-q2-earnings-raises-2015-guidance-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/celgene-q2-earnings-revenues-in-line-keeps-view-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/eli-lilly-beats-2q-earnings-wide-margin-ups-view-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/illumina-tops-q2-earnings-misses-on-revenues-eps-view-up-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/should-you-buy-amag-pharmaceuticals-amag-ahead-of-earnings-tale-of-the-tape-2015-07-22", "https://www.nasdaq.com/articles/amgens-repatha-gains-eu-nod-first-pcsk9-drug-approved-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/perrigo-prgo-to-buy-yokebe-brand-boost-eu-presence-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/isis-pharmaceuticals-begins-huntingtons-disease-study-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/gilead-gild-presents-encouraging-data-on-hiv-candidate-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/anthera-pharmaceuticals-anth-looks-good%3A-stock-up-13-tale-of-the-tape-2015-07-21", "https://www.nasdaq.com/articles/exelixis-meteoric-rise-on-positive-kidney-cancer-study-data-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/will-currency-and-generics-hit-eli-lillys-q2-earnings-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/horizon-pharma-up-on-expected-q2-sales-2015-outlook-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/biomarin-provides-update-on-phase-ii-talazoparib-study-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/bristol-myers-hiv-1-inhibitor-gets-breakthrough-designation-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/abbvie-neurodegenerative-disorder-drug-gets-orphan-status-analyst-blog-2015-07-20", "https://www.nasdaq.com/articles/can-c.r.-bard-bcr-surprise-earnings-estimates-in-q2-analyst-blog-2015-07-20", "https://www.nasdaq.com/articles/asterias-biotherapeutics-ast-looks-good%3A-stock-up-13.4-tale-of-the-tape-2015-07-17", "https://www.nasdaq.com/articles/baxalta-nektar-reveal-full-data-from-hemophilia-study-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/hospira-hsp-launches-generic-angiomax-in-the-u.s.-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/astrazeneca-strikes-deal-to-market-benralizumab-in-japan-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/amgen-reports-positive-data-on-leukemia-drug-blincyto-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/bristol-myers-opdivo-study-stopped-early-meets-endpoint-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-7.3-tale-of-the-tape-2015-07-16", "https://www.nasdaq.com/articles/ohr-pharmaceutical-jumps-on-positive-eye-drug-study-data-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/sanofi-unveils-restructuring-plans-prunes-business-units-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/mimedx-mdxg-worth-a-look%3A-stock-adds-5.3-in-session-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/synthetic-biologics-syn-in-focus%3A-stock-rises-14.6-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/cytokinetics-cytk-jumps%3A-stock-adds-6.8-in-session-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-milestone-payment-from-biogen-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/novartis-malaria-drug-gets-who-nod-for-public-procurement-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/valeant-to-buy-unilens-vision-to-boost-contact-lens-business-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/exelixis-cabozantinib-in-phase-i-for-genitourinary-cancers-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/astrazenecas-azn-oncology-drug-iressa-label-expanded-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/qiagens-egfr-test-gets-pma-nod-to-treat-lung-cancer-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/vital-therapies-vtl-looks-good%3A-stock-up-5.5-in-session-tale-of-the-tape-2015-07-13", "https://www.nasdaq.com/articles/biogen-biib-slips-2.8-lead-rd-executive-set-to-leave-analyst-blog-2015-07-13", "https://www.nasdaq.com/articles/eyegate-valeant-team-up-for-egp-437-share-gains-for-both-analyst-blog-2015-07-13", "https://www.nasdaq.com/articles/celgene-to-buy-receptos-reports-q2-preliminary-results-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/lilly-provides-update-on-necitumumab-fda-advisory-panel-analyst-blog-2015-07-10", "https://www.nasdaq.com/articles/novavax-nvax-looks-good%3A-stock-moves-11-higher-tale-of-the-tape-2015-07-10", "https://www.nasdaq.com/articles/xoma-corporation-in-focus%3A-stock-adds-20.7-in-session-tale-of-the-tape-2015-07-10", "https://www.nasdaq.com/articles/neogenomics-neo-in-focus%3A-stock-surges-25.2-tale-of-the-tape-2015-07-10", "https://www.nasdaq.com/articles/china-biologic-products-cbpo-in-focus%3A-stock-up-5.7-tale-of-the-tape-2015-07-10", "https://www.nasdaq.com/articles/astrazeneca-divests-ex-u.s.-rights-to-entocort-for-%24215m-analyst-blog-2015-07-10", "https://www.nasdaq.com/articles/aquinox-shares-nosedive-after-lead-candidate-disappoints-analyst-blog-2015-07-10", "https://www.nasdaq.com/articles/abbvie-abbv-gains-on-label-expansion-of-imbruvica-in-eu-analyst-blog-2015-07-13", "https://www.nasdaq.com/articles/3-top-ranked-health-care-stocks-buy-earnings-season-stocks-news-2015-07-09", "https://www.nasdaq.com/articles/pair-t-rowe-price-small-cap-funds-go-their-own-way-2015-07-08", "https://www.nasdaq.com/articles/dyax-hereditary-angioedema-drug-gets-breakthrough-status-analyst-blog-2015-07-08", "https://www.nasdaq.com/articles/vandas-sleep-disorder-drug-hetlioz-gains-approval-in-eu-analyst-blog-2015-07-08", "https://www.nasdaq.com/articles/dynavax-technologies-dvax-in-focus%3A-stock-up-8.2-tale-of-the-tape-2015-07-07", "https://www.nasdaq.com/articles/catabasis-up-on-fast-track-status-for-dmd-drug-cat-1004-analyst-blog-2015-07-07", "https://www.nasdaq.com/articles/isis-pharmaceuticals-lipid-disorder-drug-gets-orphan-status-analyst-blog-2015-07-07", "https://www.nasdaq.com/articles/forget-baxter-grab-these-3-medical-stocks-instead-analyst-blog-2015-07-09", "https://www.nasdaq.com/articles/use-options-chance-buy-amag-42-discount-2015-06-16", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-is-in-overbought-territory%3A-whats-next-tale-of-the-tape-2015-06", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-friday-tale-of-the-tape-2015-05-08", "https://www.nasdaq.com/articles/10-most-profitable-companies-healthcare-2015-05-07", "https://www.nasdaq.com/articles/amag-beats-on-q1-earnings-revenues-ups-view-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/use-options-chance-buy-amag-27-discount-2015-05-04", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-tuesday-tale-of-the-tape-2015-04-14", "https://www.nasdaq.com/articles/amag-down-on-cord-blood-registry-deal-for-%24700-million-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/akebia-completes-enrolment-in-phase-ii-renal-anemia-study-analyst-blog-2015-03-12", "https://www.nasdaq.com/articles/use-options-chance-buy-amag-20-discount-2015-02-27", "https://www.nasdaq.com/articles/first-week-april-17th-options-trading-amag-pharmaceuticals-2015-02-27", "https://www.nasdaq.com/articles/amags-q4-loss-narrows-y-y-reiterates-2015-outlook-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/sanofi-misses-on-q4-earnings-maintains-diabetes-guidance-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/perrigo-beats-on-earnings-fy15-guidance-in-line-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/allergan-beats-earnings-yet-again-on-strong-revenues-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/use-options-chance-buy-amag-28-discount-2015-04-01", "https://www.nasdaq.com/articles/bluebird-bios-thalassemia-drug-gets-breakthrough-status-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/amgen-reveals-positive-results-on-biosimilar-candidate-analyst-blog-2015-02-04", "https://www.nasdaq.com/articles/repros-files-for-androxal-in-the-u.s.-for-hypogonadism-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/biogen-idec-biib-shows-strength%3A-stock-moves-up-10.2-tale-of-the-tape-2015-02-02", "https://www.nasdaq.com/articles/surmodics-beats-on-q1-earnings-reaffirms-2015-guidance-analyst-blog-2015-01-30", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-jumps%3A-stock-rises-5.8-tale-of-the-tape-2015-01-30", "https://www.nasdaq.com/articles/celgene-q4-earnings-revenues-in-line-revlimid-sales-up-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/glaxo-posts-in-line-q4-earnings-hiv-segment-sales-grow-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/cel-sci-corp.-cvm-in-focus%3A-stock-adds-7.5-in-session-tale-of-the-tape-2015-01-28", "https://www.nasdaq.com/articles/minerva-neurosciences-gains-on-positive-data-on-min-202-analyst-blog-2015-01-23", "https://www.nasdaq.com/articles/endo-prices-%241.2b-senior-notes-offering-for-auxilium-deal-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-in-focus%3A-stock-rises-5.8-tale-of-the-tape-2015-01-21", "https://www.nasdaq.com/articles/bayer-announces-updates-to-european-label-of-xarelto-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/bristol-myers-makes-leadership-changes-names-new-ceo-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/hospiras-plum-36o-infusion-system-gets-fda-clearance-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/alexion-misses-on-q4-earnings-2015-outlook-disappoints-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-looks-good%3A-stock-up-7.4-tale-of-the-tape-2015-01-19", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-jumps%3A-stock-moves-up-8.9-tale-of-the-tape-2015-01-19", "https://www.nasdaq.com/articles/celgene-up-as-otezla-gains-eu-approval-for-two-indications-analyst-blog-2015-01-19", "https://www.nasdaq.com/articles/novavax-nvax-jumps%3A-stock-adds-6.4-in-session-tale-of-the-tape-2015-01-16", "https://www.nasdaq.com/articles/amgen-amgn-reveals-mixed-results-from-vectibix-studies-analyst-blog-2015-01-16", "https://www.nasdaq.com/articles/illumina-unveils-3-ngs-systems-modifies-business-strategy-analyst-blog-2015-01-16", "https://www.nasdaq.com/articles/vical-up-on-deal-with-anges-to-develop-ebola-treatment-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/actavis-gedeon-richter-present-schizophrenia-drug-data-analyst-blog-2015-01-20", "https://www.nasdaq.com/articles/cormedix-crmd-shows-strength%3A-stock-moves-up-14.6-tale-of-the-tape-2015-01-15", "https://www.nasdaq.com/articles/sarepta-starts-dosing-in-duchenne-muscular-dystrophy-study-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/illumina-declares-impressive-q4-2014-preliminary-results-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/regado-biosciences-to-merge-with-tobira-therapeutics-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/biomarin-gains-on-vimizim-2014-view-batten-disease-data-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/amgen-maintains-2015-view-expects-several-drug-launches-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/qiagen-up-on-enzymatics-unit-buy-archerdx-partnership-deal-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/astrazeneca-announces-encouraging-data-from-brilinta-study-analyst-blog-2015-01-15", "https://www.nasdaq.com/articles/celgenes-preliminary-results-2015-outlook-encouraging-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/pharmacyclics-reports-preliminary-results-and-2015-outlook-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/will-qiagens-qiasymphony-placements-weave-magic-in-2015-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/bristol-myers-opdivo-study-stopped-on-favorable-data-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/vical-incorporated-vicl-jumps%3A-stock-adds-9.5-in-session-tale-of-the-tape-2015-01-12", "https://www.nasdaq.com/articles/agenus-soars-on-immuno-oncology-agreement-with-incyte-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/conatus-announced-results-from-emricasan-studies-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/discovery-laboratories-dsco-jumps%3A-stock-rises-6.7-tale-of-the-tape-2015-01-13", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-remains-in-focus-in-2015-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/qiagen-qgen-launches-next-gen-tb-infection-test-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/affymetrix-affx-expands-genotyping-arrays-product-line-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/coherus-biosciences-chrs-jumps%3A-stock-adds-7.7-in-session-tale-of-the-tape-2015-01-09", "https://www.nasdaq.com/articles/biogen-reveals-positive-data-from-acute-optic-neuritis-study-analyst-blog-2015-01-09", "https://www.nasdaq.com/articles/abbvie-2015-earnings-guidance-projects-strong-y-y-growth-analyst-blog-2015-01-09", "https://www.nasdaq.com/articles/eli-lilly-maintains-14-view-growth-to-resume-in-2015-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/amag-provides-2014-preliminary-results-2015-guidance-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/alkermes-soars-on-positive-schizophrenia-drug-results-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-crumbles%3A-icpt-falls-9.6-in-session-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/alkermes-gains-on-positive-depression-drug-study-data-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/cytrx-jumps-on-positive-results-from-brain-cancer-study-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/salix-ceo-to-step-down-inventory-issues-remain-in-focus-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/macrocure-mcur-shows-strength%3A-stock-moves-5.4-up-tale-of-the-tape-2015-01-06", "https://www.nasdaq.com/articles/kite-pharma-kite-looks-good%3A-stock-adds-15.1-in-session-tale-of-the-tape-2015-01-06", "https://www.nasdaq.com/articles/arena-pharmaceuticals-soars-on-positive-study-results-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/akebia-progresses-with-chronic-kidney-disease-candidate-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/bristol-myers-inks-deal-for-fibrotic-disease-treatments-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/aquinox-starts-dosing-for-an-atopic-dermatitis-study-analyst-blog-2015-01-05", "https://www.nasdaq.com/articles/amgen-upgraded-to-strong-buy-is-it-in-your-portfolio-analyst-blog-2015-01-05", "https://www.nasdaq.com/articles/proqr-therapeutics-prqr-jumps%3A-stock-adds-6-in-session-tale-of-the-tape-2015-01-02", "https://www.nasdaq.com/articles/tekmira-jumped-following-update-on-its-oncology-candidate-analyst-blog-2015-01-02", "https://www.nasdaq.com/articles/hospiras-dyloject-cleared-in-the-u.s.-for-pain-management-analyst-blog-2014-12-31", "https://www.nasdaq.com/articles/kite-pharma-up-on-amgen-cancer-immunotherapy-tie-up-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-amag-pharmaceuticals-amag-stock-tale-of-the-tape-2014-12-30", "https://www.nasdaq.com/articles/amag-takeda-mutually-end-agreement-for-feraheme-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/athersys-finishes-enrollment-for-multistem-cell-therapy-trial-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/repros-gains-on-positive-updates-on-the-status-of-androxal-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/bluebird-bio-blue-soars-on-data-from-lentiglobin-study-analyst-blog-2014-12-11", "https://www.nasdaq.com/articles/bayer-files-hemophilia-a-drug-marketing-application-in-eu-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/celldexs-glembatumumab-vedotin-in-phase-ii-for-melanoma-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-12-30", "https://www.nasdaq.com/articles/cytrx-falls-on-written-fda-notice-for-aldoxorubicin-study-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/amag-pharma-amag-shares-march-higher-can-it-continue-tale-of-the-tape-2014-12-03", "https://www.nasdaq.com/articles/oncolytics-files-for-orphan-drug-designation-for-reolysin-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/mylan-gilead-ink-deal-for-taf-based-hiv-drugs-analyst-blog-2014-12-02", "https://www.nasdaq.com/articles/celgene-hits-52-week-high-on-positive-chmp-opinion-analyst-blog-2014-12-01", "https://www.nasdaq.com/articles/glaxos-ebola-candidate-well-tolerated-in-early-u.s.-study-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/uniqure-n.v.-qure-in-focus%3A-stock-soars-17.6-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/regeneron-at-52-week-high-on-eylea-priority-review-status-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-surges-10.1-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag%3A-strong-industry-solid-earnings-estimate-revisions-tale-of-the", "https://www.nasdaq.com/articles/alexions-soliris-gets-final-positive-nice-recommendation-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/mylan-myl-sued-by-baxter-for-generic-filing-of-brevibloc-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/merge-healthcare-primordial-to-improve-radiology-solutions-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/strength-seen-in-kythera-kyth%3A-stock-moves-5.5-higher-tale-of-the-tape-2014-11-26", "https://www.nasdaq.com/articles/what-makes-biodelivery-sciences-bdsi-a-strong-sell-tale-of-the-tape-2014-11-26", "https://www.nasdaq.com/articles/coronado-biosciences-inc.-cndo-in-focus%3A-stock-soars-17.6-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-on-study-initiation-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/five-prime-therapeutics-up-on-deal-with-bristol-myers-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-in-focus%3A-stock-soars-31.4-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-jumps%3A-stock-rises-8.5-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/endo-to-acquire-rights-to-testosterone-nasal-gel-natesto-analyst-blog-2014-11-25", "https://www.nasdaq.com/articles/ocera-therapeutics-ocrx-worth-watching%3A-stock-up-9.4-tale-of-the-tape-2014-11-24", "https://www.nasdaq.com/articles/enzo-biochem-enz-in-focus%3A-stock-moves-6.9-higher-tale-of-the-tape-2014-11-24", "https://www.nasdaq.com/articles/alexions-alxn-soliris-gets-orphan-drug-status-in-japan-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/xoma-corp-worth-watching%3A-stock-moves-10.3-higher-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/epirus-biopharmaceuticals-eprs-jumps%3A-stock-up-15.9-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/compugen-cgen-worth-watching%3A-stock-adds-6-in-session-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/novavax-gains-on-fast-track-designation-for-rsv-f-vaccine-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/trovagene-cancer-technology-detects-kras-mutation-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mm-398-gets-fast-track-status-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/myriads-vectra-da%3A-a-better-indicator-for-rheumatoid-arthritis-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/celgenes-pde4-inhibitor-otezla-gets-positive-chmp-opinion-analyst-blog-2014-11-24", "https://www.nasdaq.com/articles/amarin-corporation-plc-amrn-in-focus%3A-stock-soars-23.4-tale-of-the-tape-2014-11-19", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-adds-6.4-in-session-tale-of-the-tape-2014-11-19", "https://www.nasdaq.com/articles/omnicell-offers-advanced-ot-automation-at-hospital-in-riyadh-analyst-blog-2014-11-19", "https://www.nasdaq.com/articles/illumina-biomerieux-to-co-develop-ngs-epidemiology-solution-analyst-blog-2014-11-19", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-jumps%3A-stock-surges-38.3-tale-of-the-tape-2014-11-18", "https://www.nasdaq.com/articles/amicus-therapeutics-inc.-fold-in-focus%3A-stock-soars-17.8-tale-of-the-tape-2014-11-18", "https://www.nasdaq.com/articles/celldex-therapeutics-inc-cldx-focus-stock-soars-289-tale-tape-2014-11-18", "https://www.nasdaq.com/articles/argos-therapeutics-args-jumps%3A-stock-gains-7.4-tale-of-the-tape-2014-11-19", "https://www.nasdaq.com/articles/kite-pharmas-q3-loss-narrows-y-y-focus-on-pipeline-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/puma-biotechnology-slumps%3A-pbyi-tumbles-9.7-in-session-tale-of-the-tape-2014-11-17", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-ii-data-on-revusiran-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/bristol-myers-squibb-reports-positive-opdivo-phase-iii-data-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/integra-iart-strengthens-spinal-implant-with-twin-launches-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/affymetrix-affx-now-a-strong-buy-raised-guidance-positive-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-slumps%3A-icpt-falls-5.9-in-session-tale-of-the-tape-2014-11-13", "https://www.nasdaq.com/articles/kite-pharma-gains-on-positive-opinion-for-kte-c19-analyst-blog-2014-11-18", "https://www.nasdaq.com/articles/astrazeneca-amgens-brodalumab-positive-in-psoriasis-trial-analyst-blog-2014-11-13", "https://www.nasdaq.com/articles/alnylam-adds-hepatic-infectious-disease-drugs-to-pipeline-analyst-blog-2014-11-12", "https://www.nasdaq.com/articles/orexigen-turns-around-with-q3-earnings-beat-shares-soar-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/orexigen-orex-worth-watching%3A-stock-soars-33.3-tale-of-the-tape-2014-11-11", "https://www.nasdaq.com/articles/pdl-biopharmas-q3-earnings-and-revenues-increase-y-y-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/osiris-therapeutics-beats-q3-earnings-revenues-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/achillion-jumps-on-encouraging-data-on-its-hcv-candidate-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/aveo-gains-on-tivozanib-agreement-with-ophthotech-analyst-blog-2014-11-13", "https://www.nasdaq.com/articles/repros-soars-on-positive-fda-meeting-regarding-androxa-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/keryx-kerx-in-focus%3A-stock-adds-11.9-in-session-tale-of-the-tape-2014-11-07", "https://www.nasdaq.com/articles/alnylams-q3-loss-narrower-than-expected-pipeline-in-focus-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/vivus-posts-narrower-than-expected-q3-loss-revenues-up-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/myriad-genetics-down-on-earnings-revenue-miss-in-q1-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/celldex-falls-with-pipeline-update-overshadowing-q3-results-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/genomic-health-q3-loss-narrower-than-expected-revenues-lag-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/theravance-biopharma-q3-loss-widens-y-y-revenues-beat-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/repros-soars-on-positive-fda-meeting-regarding-androxa-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-q3-earnings-rise-y-y-lifts-guidance-analyst-blog-2014-11-05", "https://www.nasdaq.com/articles/mannkind-falls-on-missing-q3-estimates-yet-cuts-loss-y-y-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/integra-beats-earnings-sales-up-y-y-outlook-lowered-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/arena-pharmaceuticals-posts-in-line-q3-loss-belviq-grows-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/regeneron-q3-earnings-up-y-y-narrows-eylea-guidance-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/pharmacyclics-tops-q3-earnings-ties-up-with-astrazeneca-analyst-blog-2014-11-05", "https://www.nasdaq.com/articles/bayer-q3-earnings-grow-y-y-on-new-product-sales-view-up-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/amag-up-on-q3-earnings-beat-revenues-up-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/bind-therapeutics-inc.-bind-surges%3A-stock-rises-14.2-higher-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/affymetrix-beats-q3-earnings-revenues-raises-14-view-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/will-teva-teva-beat-q3-earnings-on-strong-generic-sales-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/will-expedia-inc.s-expe-earnings-surprise-this-season-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/theravance-thrx-falls-on-wider-than-expected-loss-in-q3-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/bayer-q3-earnings-grow-y-y-on-new-product-sales-view-up-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/sarepta-slumps-as-eteplirsen-nda-submission-gets-delayed-analyst-blog-2014-10-28", "https://www.nasdaq.com/articles/allergan-beats-on-earnings-revenues-valeant-raises-offer-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-monday-tale-of-the-tape-2014-10-27", "https://www.nasdaq.com/articles/can-corning-glw-surprise-earnings-estimates-this-season-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/will-baidu-bidu-disappoint-q3-earnings-estimates-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/will-abbvie-abbv-disappoint-in-this-earnings-season-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/can-the-rally-in-amag-pharmaceuticals-amag-shares-continue-tale-of-the-tape-2014-10-02", "https://www.nasdaq.com/articles/amag-up-on-roughly-%241b-deal-with-lumara-to-widen-portfolio-analyst-blog-2014-09-30", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-slightly-lower-amag-pharma-springs-higher-675-mln-deal", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-29", "https://www.nasdaq.com/articles/amag-pharmaceuticals-amag-is-overbought%3A-is-a-drop-coming-tale-of-the-tape-2014-09-05", "https://www.nasdaq.com/articles/amag-pharmaceuticals-q2-loss-narrows-as-feraheme-sales-rise-analyst-blog-2014-07-30", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-hang-small-gains-amag-pharma-climbs-after-topping-analyst", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-gdxj-2014-10-23", "https://www.nasdaq.com/articles/why-amag-pharmaceuticals-amag-could-be-positioned-for-a-slump-tale-of-the-tape-2014-07-28", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/amag-pharma-amag-is-in-overbought-territory%3A-whats-next-tale-of-the-tape-2014-07-02", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-tuesday-tale-of-the-tape-2014-06-24", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-amag-analyst-blog-2014-04-25", "https://www.nasdaq.com/articles/wider-than-expected-q4-loss-at-amag-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/amag-slides-on-regulatory-setback-analyst-blog-2014-01-23", "https://www.nasdaq.com/articles/sector-update-health-care-2014-07-29", "https://www.nasdaq.com/articles/update-on-amags-feraheme-analyst-blog-2014-01-09", "https://www.nasdaq.com/articles/biomarin-seeks-canadian-approval-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/positive-data-on-chemocentryx-candidate-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/ambi-plunges-on-disappointing-fda-news-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/cytokinetics-progresses-with-tirasemtiv-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/mygn-unveils-prolaris-study-results-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/oculus-gains-on-scar-product-approval-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/amags-feraheme-revs-look-good-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/affymetrix-remains-outperform-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/mygn-battles-odds-shares-fall-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/fda-agrees-to-bdsis-phase-iii-program-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/orphan-drug-status-for-cnats-emricasan-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-jumps%3A-stock-rises-6.6-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/xoma-corporation-xoma-worth-watching%3A-stock-surges-22.2-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/mimedx-group-mdxg-in-focus%3A-stock-moves-up-5.9-tale-of-the-tape-2013-12-02", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/aeterna-zentaris-closes-public-offering-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/bayer-hits-52-week-high-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/amag-raised-to-strong-buy-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2013-11-29", "https://www.nasdaq.com/articles/mdco-progresses-with-fibrocaps-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/dynavax-technologies-dvax-catches-eye%3A-stock-rises-5.2-tale-of-the-tape-2013-11-25", "https://www.nasdaq.com/articles/athersys-athx-jumps%3A-stock-rises-by-9.2-tale-of-the-tape-2013-11-22", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-up-5.2-tale-of-the-tape-2013-12-02", "https://www.nasdaq.com/articles/vertex-monetizes-incivo-royalty-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/amag-upgraded-to-strong-buy-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-11-20", "https://www.nasdaq.com/articles/fda-go-ahead-for-illuminas-offerings-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/synta-pharmaceuticals-snta-catches-eye%3A-stock-surges-15.2-tale-of-the-tape-2013-11-19", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-in-focus%3A-stock-jumps-7.7-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/aegerion-pharmaceuticals-aegr-catches-eye%3A-stock-up-5.5-tale-of-the-tape-2013-11-22", "https://www.nasdaq.com/articles/dendreon-narrows-loss-provenge-disappoints-again-analyst-blog-2013-11-15", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-thursday-tale-of-the-tape-2013-11-14", "https://www.nasdaq.com/articles/fda-accepts-nps-pharmas-snda-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/medicines-co.-gains-on-qidp-status-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-inc.-vnda-grabs-attention%3A-stock-shoots-95.9-tale-of-the-tape-2013", "https://www.nasdaq.com/articles/astrazeneca-to-invest-in-new-zoladex-facility-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/aveo-q3-loss-wider-than-expected-shares-down-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-worth-watching%3A-stock-up-11.9-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-worth-a-look%3A-stock-surges-10.6-tale-of-the-tape-2013-11-12", "https://www.nasdaq.com/articles/rigel-narrows-loss-shares-continue-to-fall-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/loss-narrows-at-repros-shares-down-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/geron-q3-loss-in-line-shares-up-on-ash-abstract-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/pcyc-beats-on-earnings-and-revs-in-q3-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-worth-a-look%3A-stock-surges-24.12-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/jazz-pharma-upgraded-to-strong-buy-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/chelsea-therapeutics-chtp-worth-watching%3A-stock-surges-11-tale-of-the-tape-2013-11-12", "https://www.nasdaq.com/articles/genomic-health-tops-q3-earnings-ests-analyst-blog-2013-11-08", "https://www.nasdaq.com/articles/earnings-beat-at-surmodics-in-q4-analyst-blog-2013-11-07", "https://www.nasdaq.com/articles/npsps-loss-narrows-shares-down-on-weak-forecast-analyst-blog-2013-11-07", "https://www.nasdaq.com/articles/ariad-shares-tumble-on-iclusig-woes-analyst-blog-2013-11-07", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-seattle-genetics-analyst-blog-2013-11-07", "https://www.nasdaq.com/articles/q1-earnings-beat-at-mygn-revs-outperform-analyst-blog-2013-11-06", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-endocyte-analyst-blog-2013-11-06", "https://www.nasdaq.com/articles/narrower-than-expected-q3-loss-at-nektar-analyst-blog-2013-11-08", "https://www.nasdaq.com/articles/genomic-health-tops-q3-earnings-ests-analyst-blog-2013-11-08", "https://www.nasdaq.com/articles/impax-earnings-fall-on-lower-revenues-analyst-blog-2013-11-05", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-mannkind-analyst-blog-2013-11-05", "https://www.nasdaq.com/articles/osiris-up-on-q3-earnings-analyst-blog-2013-11-05", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-pacira-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/vrtx-shares-down-on-q3-results-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/dr.-reddys-beats-on-earnings-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/update-on-repros-pipeline-analyst-blog-2013-11-06", "https://www.nasdaq.com/articles/q3-loss-at-aegerion-narrower-than-expected-analyst-blog-2013-10-31", "https://www.nasdaq.com/articles/affymetrix-beats-on-q3-earnings-analyst-blog-2013-10-31", "https://www.nasdaq.com/articles/antiviral-franchise-powers-earnings-beat-at-gilead-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/avanir-gives-preliminary-update-on-fiscal-year-2013-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/qiagen-beats-both-earnings-and-revs-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/anacor-valeant-settle-disputes-analyst-blog-2013-10-29", "https://www.nasdaq.com/articles/actavis-q3-earnings-grow-guides-up-analyst-blog-2013-10-29", "https://www.nasdaq.com/articles/novo-nordisk-beats-on-earnings-lags-sales-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/illumina-tops-earnings-ups-guidance-analyst-blog-2013-10-22", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-10-21", "https://www.nasdaq.com/articles/alimera-down-on-3rd-iluvien-crl-analyst-blog-2013-10-21", "https://www.nasdaq.com/articles/anacor-shares-rise-on-favorable-arbitration-analyst-blog-2013-10-21", "https://www.nasdaq.com/articles/strength-seen-in-alkermes-alks%3A-stock-up-8.5-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/positive-data-on-omeros-oms824-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/fda-approves-novo-nordisks-novoeight-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/narrower-q3-loss-at-amag-analyst-blog-2013-10-24", "https://www.nasdaq.com/articles/another-milestone-for-isis-pharma-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/fda-delays-verdict-for-amags-feraheme-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-10-16", "https://www.nasdaq.com/articles/amag-pharmaceuticals-inc.-enters-oversold-territory-tale-of-the-tape-2013-10-16", "https://www.nasdaq.com/articles/good-news-for-catalyst-pharmas-pipeline-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/insmeds-arikace-makes-progress-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/encouraging-data-on-protalix-candidate-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/actelion-beats-on-earnings-and-revenues-in-q3-analyst-blog-2013-10-17", "https://www.nasdaq.com/articles/new-patent-issued-for-amags-feraheme-analyst-blog-2013-08-09", "https://www.nasdaq.com/articles/astellas-fibrogen-start-phase-ii-study-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-amag-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/label-expansion-sought-for-amag-tkpyys-rienso-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/swiss-issue-for-amag-takedas-rienso-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/market-wrap-wednesday-may-22-stocks-pullback-bernanke-says-bond-buying-could-slow-2013-05", "https://www.nasdaq.com/articles/amag-narrows-loss-maintains-view-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/amag-shares-skid-on-fda-notification-analyst-blog-2013-09-26", "https://www.nasdaq.com/articles/fda-action-date-for-amag-drug-analyst-blog-2013-03-11", "https://www.nasdaq.com/articles/amag-narrows-loss-maintains-view-analyst-blog-2013-03-04", "https://www.nasdaq.com/articles/amag-gives-4q12-snapshot-analyst-blog-2013-01-07", "https://www.nasdaq.com/articles/amag-seeks-feraheme-label-expansion-analyst-blog-2012-12-27", "https://www.nasdaq.com/articles/amag-presents-feraheme-data-analyst-blog-2012-12-11", "https://www.nasdaq.com/articles/amags-rienso-launched-in-the-eu-analyst-blog-2012-11-12", "https://www.nasdaq.com/articles/amag-cuts-loss-guides-favorably-analyst-blog-2012-11-05", "https://www.nasdaq.com/articles/positive-results-on-amags-feraheme-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/amag-beats-expectations-analyst-blog-2012-08-01", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2012-07-27", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-26-2012-mmm-pld-agco-abb-alk-alks-ddd-asps-aciw-aixg-alu", "https://www.nasdaq.com/articles/amag-streamlines-operations-analyst-blog-2012-06-26", "https://www.nasdaq.com/articles/amags-rienso-cleared-in-the-eu-analyst-blog-2012-06-25", "https://www.nasdaq.com/articles/amag-beats-riding-on-feraheme-sales-analyst-blog-2012-05-02", "https://www.nasdaq.com/articles/allos-eyed-by-spectrum-pharma-analyst-blog-2012-04-09", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2012-10-10", "https://www.nasdaq.com/articles/revenues-decline-at-amag-analyst-blog-2012-03-08", "https://www.nasdaq.com/articles/chinas-slashed-growth-forecast-weighs-stock-futures-2012-03-05", "https://www.nasdaq.com/articles/allos-therapeutics-cut-to-neutral-analyst-blog-2012-01-12", "https://www.nasdaq.com/articles/amag-q4-sales-set-to-disappoint-analyst-blog-2012-01-11", "https://www.nasdaq.com/articles/amags-feraheme-gets-canada-nod-analyst-blog-2011-12-15", "https://www.nasdaq.com/articles/allos-continues-to-outperform-analyst-blog-2011-11-25", "https://www.nasdaq.com/articles/amag-hires-financial-advisor-analyst-blog-2011-11-18", "https://www.nasdaq.com/articles/allos-upped-to-outperform-analyst-blog-2012-03-22", "https://www.nasdaq.com/articles/stocks-rally-european-debt-summit-optimism-december-crude-surges-over-2-2011-10-21", "https://www.nasdaq.com/articles/mid-day-update-stocks-surge-indexes-top-1-europe-debt-optimism-earnings-2011-10-21", "https://www.nasdaq.com/articles/top-10-list-unusual-option-activity-2011-10-07", "https://www.nasdaq.com/articles/options-ideas-24-healthcare-stocks-bullish-options-sentiment-2011-06-07", "https://www.nasdaq.com/articles/4-biotech-stocks-could-pop-2011-05-18", "https://www.nasdaq.com/articles/buy-signal-biotechs-best-value-play-2010-11-30", "https://www.nasdaq.com/articles/todays-earnings-movers-tnav-mww-cstr-gmo-axti-higher-nr-nuva-amag-ostk-gww-lower-2010-10", "https://www.nasdaq.com/articles/mid-day-update-stocks-pare-some-early-losses-unemployment-claims-lift-sentiment-2011-11-17", "https://www.nasdaq.com/articles/options-trade-day-ratio-call-spread-amag-pharmaceuticals-inc-2010-09-27", "https://www.nasdaq.com/articles/iron-safety-hits-amag-pharmaceuticals-2010-02-04", "https://www.nasdaq.com/articles/looking-value-septembers-biggest-losers-2010-10-04"], "Content": []}